Mazor Robotics (MZOR) 20-F 30 Apr 18 2017 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2017shares
Document And Entity Information
Entity Registrant Name	MAZOR ROBOTICS LTD.
Entity Central Index Key	1,566,844
Document Type	20-F
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	Yes
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding	52,082,735
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	$ 46,376	$ 14,954
Short-term investments	56,708	37,862
Trade receivables	5,460	8,225
Other current assets	2,054	1,728
Inventory	7,864	4,715
Total current assets	118,462	67,484
Long-term investments	5,171	9,017
Property and equipment, net	4,323	3,615
Intangible assets, net	1,925	2,258
Trade receivables	596
Other non-current assets	519	351
Total non-current assets	12,534	15,241
Total assets	130,996	82,725
Liabilities
Trade payables	3,474	5,018
Deferred revenue	3,471	4,031
Other current liabilities	9,874	8,462
Total current liabilities	16,819	17,511
Non-current liabilities - Employee benefits	414	325
Total liabilities	17,233	17,836
Equity
Share capital	136	124
Share premium	225,678	174,647
Amounts allocated to warrants	9,629
Capital reserve for share-based payment transactions	10,480	9,859
Foreign currency translation reserve	2,119	2,119
Accumulated loss	(134,279)	(121,860)
Total equity	113,763	64,889
Total liabilities and equity	$ 130,996	$ 82,725

Consolidated Income Statements

Consolidated Income Statements - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Profit or loss [abstract]
Revenues	$ 64,947	$ 36,379	$ 26,096
Cost of sales	23,684	10,330	5,827
Gross profit	41,263	26,049	20,269
Research and development expenses, net	8,192	5,736	6,324
Selling and marketing expenses	39,499	33,637	24,947
General and administrative expenses	7,375	5,697	4,305
Operating loss	(13,803)	(19,021)	(15,307)
Financing income	1,247	438	272
Financing expenses	(19)	(41)	(137)
Financing income, net	1,228	397	135
Loss before taxes on income	(12,575)	(18,624)	(15,172)
Income tax expense (benefit)	(156)	44	213
Net loss	$ (12,419)	$ (18,668)	$ (15,385)
Net loss per share
Basic and diluted loss per share (in USD)	$ (0.25)	$ (0.42)	$ (0.36)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Share Capital [Member]		Share premium [Member]	Amounts allocated to share warrants [Member]	Capital reserve for share-based payment transactions [Member]	Foreign currency translation reserve [Member]	Accumulated loss [Member]	Total
Balance at Dec. 31, 2014	$ 110		$ 135,182	$ 77	$ 4,586	$ 2,119	$ (87,807)	$ 54,267
Loss for the year							(15,385)	(15,385)
Exercise of share options		[1]	904		(477)			427
Expiration of share options			21		(21)
Share-based payments					3,091			3,091
Balance at Dec. 31, 2015	110		136,107	77	7,179	2,119	(103,192)	42,400
Loss for the year							(18,668)	(18,668)
Issuance of shares and warrants	11		31,386					31,397
Exercise of share options	3		6,549		(2,142)			4,410
Exercise of warrants			558	(77)				481
Expiration of share options			47		(47)
Share-based payments					4,869			4,869
Balance at Dec. 31, 2016	124		174,647		9,859	2,119	(121,860)	64,889
Loss for the year							(12,419)	(12,419)
Issuance of shares and warrants	6		30,343	9,629				39,978
Exercise of share options	6		20,688		(5,749)			14,945
Share-based payments					6,370			6,370
Balance at Dec. 31, 2017	$ 136		$ 225,678	$ 9,629	$ 10,480	$ 2,119	$ (134,279)	$ 113,763
[1]	Represents an amount less than USD 1 thousand.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Loss for the year	$ (12,419)	$ (18,668)	$ (15,385)
Adjustments:
Depreciation and amortization	1,522	822	527
Financing income, net	(291)	(275)	(207)
Gain on sale of property and equipment		(6)
Share-based payments	6,370	4,439	3,091
Income tax expense (benefit)	(156)	44	213
Total Adjustments	7,445	5,024	3,624
Change in inventory	(3,224)	(1,938)	273
Change in trade and other accounts receivable	1,852	(3,512)	(2,408)
Change in prepaid lease fees	(39)	(20)	6
Change in trade and other accounts payable	(138)	8,723	2,217
Change in employee benefits	89	26	21
Change in decrease increase in assets and liabilities	(1,460)	3,279	109
Interest received	554	301	194
Income tax paid	(11)	(38)	(114)
Income tax and interest received and paid	543	263	80
Net cash used in operating activities	(5,891)	(10,102)	(11,572)
Cash flows from investing activities
Proceeds from (purchase of) short-term investments, net	(10,463)	(11,094)	9,816
Purchase of long-term investments	(4,537)	(9,823)	(7,538)
Proceeds from sale of long-term investments		748	992
Capitalization of development costs		(1,902)
Purchase of property and equipment	(2,364)	(2,361)	(702)
Net cash provided by (used in) investing activities	(17,364)	(24,432)	2,568
Cash flows from financing activities
Proceeds from issuance of ADR's and warrants, net	39,988	31,416
Proceeds from exercise of share options by employees and service providers	14,945	4,100	370
Proceeds from exercise of warrants by investors		481
Net cash provided by financing activities	54,933	35,997	370
Net (decrease) increase in cash and cash equivalents	31,678	1,463	(8,634)
Cash and cash equivalents at the beginning of the year	14,954	13,519	22,255
Effect of exchange rate differences on cash and cash equivalents	(256)	(28)	(102)
Cash and cash equivalents at the end of the year	46,376	14,954	13,519
Supplementary cash flows information:
Transfer of inventory to property and equipment, net	75
Purchase of property and equipment on credit	(24)	(566)
Issuance costs on credit	$ (10)	$ (19)

Reporting Entity

Reporting Entity	12 Months Ended
	Dec. 31, 2017
Disclosure of reporting entity [Abstract]
Reporting Entity	Note 1 - Reporting Entity. A. Mazor Robotics Ltd. (the “Company”) is an Israeli company incorporated in Israel. The address of the Company’s registered office is 5 Shacham St., North Industrial Park, Caesarea, Israel. These consolidated financial statements as of and for the year ended December 31, 2017 comprise the Company and its wholly owned subsidiaries incorporated in the United States (U.S.) and Singapore, Mazor Robotics Inc. and Mazor Robotics Pte. Ltd., respectively (together referred to as the “Group”). The Group is a leading innovator in spine surgery and has pioneered surgical robotic-guidance systems and complementary products in the spine and brain surgical markets that enable B. Definitions In these financial statements - (1) The Company (2) The Group (3) Subsidiary (4) Related party “Related Party Disclosures.” C. Material events in the reporting period Lead Sharing Distribution Agreement and Purchase Agreement with Medtronic plc. On May 16, 2016, the Company entered into two strategic agreements with Medtronic. One agreement is a two-phase Exclusive Lead Sharing and Distribution Agreement. The second agreement was a Purchase Agreement, which provided for an equity investment by Medtronic in Company. In August the Company and Medtronic amended and restated the original Exclusive Lead Sharing and Distribution Agreement and entered into the second phase, Medtronic will assume exclusive global sales and distribution rights for the Mazor X system Exclusive Lead Sharing and Distribution Agreement The exclusive lead sharing and distribution agreement is a commercial agreement which had an initial U.S.-based co-promotion phase. Subject to meeting certain milestones defined in the agreement, and the parties’ mutual decision to proceed, the relationship enters a second phase. During the second phase, Medtronic will assume exclusive global sales and distribution rights for the Mazor X system. In August 2017, the Company and Medtronic entered the second phase of its strategic partnership. The agreements provide for the conversion of the commercial relationship between the parties, with Medtronic assuming exclusive worldwide distribution of the Mazor X system, and Medtronic making a third tranche investment in the Company. These developments are a result of the early achievement of certain sales and marketing milestones by both companies, as well as higher than expected global market acceptance and demand for the Mazor X system. As a part of the agreement, Medtronic assumed exclusive global commercial responsibility for the Mazor X surgical robotic-guidance and its accessories in the spine market. The agreement also provided for a co-development of future products for the spine market that combine the Company’s core expertise in surgical planning and precision-guided surgical systems with Medtronic’s navigation capabilities and implant systems. Purchase The Purchase Agreement provides for a three-tranche equity investment in the Company. In the first tranche, which closed in May 2016, Medtronic purchased from the Company’s newly issued 2,085,984 Ordinary Shares, representing 1,042,992 ADSs, at a price per ADS of $11.42, for a total of $11.9 million, before deducting issuance expenses payable by the Company. In the second tranche, which closed in August 2016, the Company issued 1,831,384 Ordinary Shares, representing 915,692 ADSs. The price per ADS in the second tranche was $21.84, or a total of $20 million, before deducting issuance expenses payable by the Company. In the third tranche, which closed in September 2017, Medtronic purchased newly issued 1,040,107 ADSs, representing 2,080,214 Ordinary Shares The price per ADS in the third tranche was $38.46. As part of this transaction, The Company also issued to Medtronic warrants to purchase an additional 1,210,000 of the Company’s ADSs at an exercise price of $44.23 per ADS. Medtronic has the right to exercise the warrants immediately in whole or in part, for cash, and they expire after 18 months. Total consideration for the ADSs and the warrants amounted to approximately $40 million, before deducting issuance expenses payable by the Company.

Basis of Preparation

Basis of Preparation	12 Months Ended
	Dec. 31, 2017
Disclosure of basis of preparation [Abstract]
Basis of Preparation	Note 2 - Basis of Preparation A. Statement of compliance The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements were authorized for issue by the Company’s Board of Directors on April 30, 2018. B. Reporting and functional currency These consolidated financial statements are presented in US dollars (“USD”), and have been rounded to the nearest thousands, except when otherwise indicated. The USD is the currency that represents the principal economic environment in which the Company operates. C. Basis of measurement The financial statements have been prepared on the historical cost basis except for certain investments and derivative instruments measured at fair value through profit or loss, inventory (measured at the lower of cost or net realizable value), deferred tax assets and liabilities and assets and liabilities for employee benefits. For further information regarding the measurement of these assets and liabilities see Note 3 regarding significant accounting policies. D. Use of estimates and judgments The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The preparation of accounting estimates used in the preparation of the Company’s financial statements requires management to make assumptions regarding circumstances and events that involve considerable uncertainty. Management of the Company prepares the estimates on the basis of past experience, various facts, external circumstances, and reasonable assumptions according to the pertinent circumstances of each estimate. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any affected future periods. Material accounting estimates and judgments Presented hereunder is information with respect to material assumptions and estimates, which were made by the Group’s management while implementing Group accounting policies: Recognition of deferred tax assets in respect of tax losses Management of the Company evaluates whether it is probable that in the foreseeable future there will be taxable profits against which losses and tax credits can be utilized and quantify the portion of tax losses that are more likely than not to be allowable under applicable tax laws, accordingly it recognizes (or does not recognize) deferred tax assets. For further information on losses for which a deferred tax asset was recognized, see Note 12 regarding taxes on income. Fair value measurement of share-based payment transactions The Group grants share-based payment to directors, management, employees and consultants. The fair value of the share options is measured at grant date on the basis of accepted valuation models and assumptions regarding unobservable inputs used in the valuation models. The value of the transactions, measured as described above, is recognized as an expense over the vesting period. Concurrently with the periodic recognition of an expense, an increase is recognized in a capital reserve, within the Group’s equity. The Company used certain estimates in regards to revenue recognition as presented hereunder note 3J. E. New standards and interpretations not yet adopted (1) IFRS 16, Leases (“IFRS 16”) IFRS 16 replaces International Accounting Standard 17 - Leases (IAS 17) and its related interpretations. For lessees, the standard presents a unified model for the accounting treatment of most leases according to which the lessee has to recognize an asset and liability in respect of the lease in its financial statements. IFRS 16 is applicable for annual periods as of January 1, 2019, with the possibility of early adoption, so long as the company has also early adopted IFRS 15, Revenue from Contracts with Customers. The Company affect (2) IFRS 15, Revenue from Contracts with Customers (“IFRS 15”) IFRS 15 replaces the current guidance regarding recognition of revenues and presents a comprehensive framework for determining whether revenue should be recognized and when and at what amount. IFRS 15 is applicable for annual periods beginning on or after January 1, 2018 and earlier application is permitted. The Company will adopt as of January 1, 2018. The Company has completed its assessment of revenue from existing contracts with customers and is of the opinion that there is no significant effect on its revenue recognition practices, financial position, results of operations or cash flows. A majority of the Company’s revenues derive from product sales, for which the performance obligations are met with the transfer of control and revenue is recognized when the products are delivered. For customer services, the performance obligation is satisfied over time and therefore revenue is recognized, over the period of rendering of the service. The revenue recognition model described above is consistent with the Company’s previous revenue recognition practice. Therefore, the Company will (3) IFRS 9 (2014), Financial Instruments (“IFRS 9 (2014)”) IFRS 9 (2014) replaces the current guidance in IAS 39, Financial Instruments: Recognition and Measurement IFRS 9 (2014) is effective for annual periods beginning on or after January 1, 2018 with early adoption being permitted. The Company has examined the effects of applying IFRS 9 (2014), and in its opinion the effect on the financial statements will be immaterial.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Disclosure of significant accounting policies [Abstract]
Significant Accounting Policies	Note 3 - Significant Accounting Policies The accounting policies set out below have been applied consistently for all periods presented in these consolidated financial statements. A. Basis of consolidation (1) Subsidiaries Subsidiaries are entities controlled by the Group. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. (2) Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment. B. Foreign currency transactions Transactions in foreign currencies are translated to the respective functional currencies of Group entities at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the year, adjusted for effective interest and payments during the year, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period. Foreign currency differences arising on translation are recognized in profit or loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. C. Financial instruments (1) Non-derivative financial assets Initial recognition of financial assets The Group initially recognizes loans, receivables and deposits on the date that they are originated. All other financial assets acquired in a regular way purchase, including assets designated at fair value through profit or loss, are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument (i.e., on the date the Group undertook to purchase or sell the asset). Non-derivative financial instruments comprise investments in marketable securities, deposits, trade and other receivables, and cash and cash equivalents. De-recognition of financial assets Financial assets are de-recognized when the Group’s contractual rights to the cash flows from the asset expire, or when the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred. Any interest in transferred financial assets that is created or retained by the Group is recognized as a separate asset or liability. Regular way sales of financial assets are recognized, or de-recognized, on the trade date, which is the date that the Company undertook to purchase, or sell the assets. See (2) hereunder regarding the offset of financial assets and financial liabilities. The Group classifies its financial assets according to the following categories: Financial assets at fair value through profit or loss A financial asset is classified at fair value through profit or loss, if it is classified as held for trading. Attributable transaction costs are recognized in profit or loss as incurred. Financial assets at fair value through profit or loss are measured at fair value, and changes therein are recognized in profit or loss. Financial assets held for trading are comprised mainly of investments in marketable securities. Loans and receivables Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are recognized initially at fair value plus any direct attributable transaction costs. Subsequent to initial recognition, loans and receivables are measured at amortized cost using the effective interest method, less any impairment losses. Loans and receivables are comprised of trade receivables, deposits, other accounts receivable and cash and cash equivalents. Cash and cash equivalents are comprised of cash balances available for immediate use and call deposits. Cash equivalents are comprised of short-term highly liquid investments (with original maturities of three months or less) that are readily convertible into known amounts of cash and are not exposed to significant risks of change in value. (2) Non-derivative financial liabilities Financial liabilities are recognized initially on the trade date, at which the Group becomes a party to the contractual provisions of the instrument. Financial liabilities are de-recognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged or cancelled. Financial liabilities are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Non-derivative financial liabilities comprise of, trade and other accounts payable. Financial assets and liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group currently has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. (3) CPI-linked assets and liabilities that are not measured at fair value The value of CPI-linked financial assets and liabilities, which are not measured at fair value, is revalued every period in accordance with the actual increase/decrease in the CPI. (4) Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized as a deduction from equity. (5) Share options and warrants Receipts in respect of share options are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price. D. Property and Equipment (1) Recognition and measurement Property and equipment Cost includes expenditure that is directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and direct labor, any other costs directly attributable to bringing the assets to a working condition for their intended use. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment. Spare parts, servicing equipment and stand-by equipment are to be classified as fixed assets when they meet the definition of fixed assets in IAS 16, and are otherwise to be classified as inventory. Gains and losses on disposal of property and equipment are determined by comparing the net proceeds from disposal with the carrying amount of the asset, and are recognized net within the relevant line item in profit or loss. (2) Subsequent costs The cost of replacing part of a property and equipment asset item is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Group and its cost can be measured reliably. The carrying amount of the replaced part is de-recognized. The costs of day-to-day servicing are recognized in profit or loss as incurred. (3) Depreciation Depreciation is a systematic allocation of the depreciable amount of an asset over its useful life. The depreciable amount is the cost of the asset, or other amount substituted for cost. An asset is depreciated from the date it is ready for use, meaning the date it reaches the location and condition required for it to operate in the manner intended by management. Depreciation is recognized in profit or loss on a straight-line basis over the estimated useful lives of the property and equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows: Computers and equipment 3 years Machinery and equipment 3-10 years Motor vehicles 7 years Office furniture and equipment 6-17 years Leasehold improvements The shorter of the lease term and the useful life Depreciation methods and useful lives are reviewed at each financial year-end and adjusted, if appropriate. E. Intangible assets (1) Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involve plans or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if: · development costs can be measured reliably; · the product or process is technically and commercially feasible; · future economic benefits are probable; and · the Group intends to and has sufficient resources to complete development and to use or sell the asset. With regard to some of the Company’s products, technical feasibility may occur only after the Company receives approval from the U.S. Food and Drug Administration (the FDA). Sometimes the costs incurred between the successful completion of the product’s development and successful trials, and the time the product is ready for sale are immaterial, so that in reality all of the development costs might be recognized in profit or loss, as incurred. Any capitalized expenditure includes the cost of materials, direct labor and other related costs that are directly attributable to developing the asset for its intended use. Other development expenditures are recognized in profit or loss as incurred. In subsequent periods, capitalized development expenditure will be measured at cost less accumulated amortization and accumulated impairment losses. (2) Subsequent expenditure Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated brands, is recognized in profit or loss, as incurred. (3) Amortization Amortization is a systematic allocation of the amortizable amount of an intangible asset over its useful life. The amortizable amount is the cost of the asset. Amortization is recognized in profit or loss, on a straight-line basis over the estimated useful lives of the intangible assets, from the date they are available for use, since these methods most closely reflect the expected pattern of consumption of the future economic benefits embodied in each asset. Management estimates the useful life of the capitalized development costs as 7 years. Amortization methods and useful lives are reviewed at each reporting date and adjusted if appropriate. F. Inventory Inventory is measured at the lower of cost and net realizable value. The cost of inventory is based on the moving average method, and includes expenditure incurred in acquiring the inventory and the costs incurred in bringing it to its existing location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. Management regularly evaluates the necessity of provisions for obsolescence, which may result from excess, slow-moving or obsolete inventories. G. Impairment (1) Non-derivative financial assets A financial asset not carried at fair value through profit or loss is tested for impairment when objective evidence indicates that one or more events had a negative effect on the estimated future cash flows of the asset. Objective evidence that financial assets are impaired may include: • default by a debtor; • indications that a debtor or issuer will enter bankruptcy; or • observable data indicating a measurable decrease in the cash flow expected from a group of financial assets. An impairment loss is reversed if the reversal can be related objectively to an event occurring after the recognition of the impairment loss. For financial assets measured at amortized cost the reversal is recognized in profit or loss. (2) Non-financial assets The carrying amounts of the Group’s non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its net selling price (fair value less costs to sell the asset). In assessing value in use, the estimated future cash flows are discounted to their present value using a discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or cash-generating unit, for which the estimated future cash flows from the asset or cash-generating unit were not adjusted. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets. An impairment loss is recognized if the carrying amount of an asset or its cash-generating unit exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss. Impairment losses recognized in respect of cash-generating units are allocated to reduce the carrying amounts of each of the assets in the cash-generating unit on a pro rata basis. Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized initially. H. Employee benefits (1) Post-employment benefits Most of the Group’s Israeli employees are subject to Section 14 of the Israeli Severance Pay Law - 1963 and therefore substantially all of the post-employment plans of the Group are classified as defined contribution plans. Defined contribution plans Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which services are rendered by employees. Long-term benefits are presented on a discounted basis and are immaterial to the financial statements. (2) Short-term benefits Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided, or upon the actual absence of the employee when the benefit is not accumulated. A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. The employee benefits are classified as short-term benefits or as other long-term benefits depending on when the Company expects the benefits to be wholly settled. (3) Share-based payment transactions The fair value of share-based payment, measured on the grant date, granted to employees is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect the number of awards that are expected to vest. I. Provisions A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. J. Revenue Recognition General The Group recognizes revenue in accordance with IAS 18, Revenue Recognition · the significant risks and rewards of ownership of the goods have been transferred to the customer; · it is probable that the economic benefits associated with the transaction will flow to the Group; · the costs incurred or to be incurred in respect of the transaction can be measured reliably; · the Group retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; and · the amount of revenue can be measured reliably. The revenue from sales in the ordinary course of business is measured according to the fair value of the consideration received or receivable, which is based on the selling price of each component, net of discounts. In general, the Group’s sales agreements include several components: · surgical robotic-guidance systems (“Systems”); · disposable components; · related re-usable accessories; and · warranty and maintenance services related to the Systems sold, which includes spare parts, software updates, preventive maintenance and on-call support as detailed in the agreement. These components are split into separate accounting units if and only if each component has separate value for the customer and there is reliable evidence of the fair value of the components not yet supplied. Components not split into a separate accounting unit due to non-compliance with the above conditions, are grouped together as a single accounting unit. The revenue from each such accounting unit is recognized upon fulfillment of the conditions for recognition of revenue from the components included therein, according to their type. The allocation of consideration from a revenue arrangement to its separate units of account is based on the relative fair values of each unit. If the fair value of the delivered item is not reliably measurable, then revenue is allocated based on the difference between the total arrangement consideration and the fair value of the undelivered item. Usually, fair value of the warranty and maintenance services component is determined based on the renewal quote offered in the sales agreement. The timing of revenue recognition from the various components is as follows: Sales of Systems · Sales to end customers - Upon the completion of installation of the System, training of at least one surgeon, which typically occurs prior to or concurrent with the System installation, and customer acceptance, if required. · Sales to distributors - Upon delivery to the distributor, according to contractual delivery terms, provided that the significant risks and rewards of ownership of the System are transferred to the distributor upon delivery, the distributor has no right of return, receipt of the consideration is probable and not dependent on the distributor’s ability to collect from the end customer, the commitment to carry out installation and training for the end customer lies with the distributor and that the distributor has been authorized to perform the installation and training for the end customers, or if the distributor has the ability to perform the installation and training for the end customer independently. If the above conditions are not met, the Group recognizes revenue at the time of fulfillment of the conditions for recognition of revenue from the end customer For System sales, where a commitment for future trade-in exists, the Company examines whether the transaction meets all revenue recognition criteria. If one or more of the revenue recognition criteria are not met, revenue is deferred and the System is presented in inventory until the earliest of trade-in commitment is fulfilled, or trade-in option expire. In rare circumstances, the Company may bill a customer for a product and retain physical possession of the product until it is transferred to the customer at a point in time in the future. If such delivery is delayed at the customer’s request and the customer assumes title and accepts billing, revenue is recognized when the buyer takes title, provided that: (i) it is probable that the delivery will be made; (ii) the item is on hand, identified and ready for delivery to the customer at the time the sale is recognized; (iii) the customer specifically acknowledges the deferred delivery instructions, and (iv) the usual payment terms apply. Disposable components sales · In sales to end customers - Upon delivery. · In sales to distributors - Upon delivery to the distributor, provided that the significant risks and rewards of ownership of the components are transferred to the distributor upon delivery, the distributor has no right of return and that the receipt of the consideration is probable and not dependent on the distributor’s ability to collect from the end customer. Warranty and maintenance services (“Services”) K. Leases Leases are classified as operating leases, and the leased assets are not recognized on the Group’s statement of financial position. Payments made under operating leases, are recognized in profit or loss on a straight-line basis over the term of the lease. L. Financing income and expenses Financing income is comprised of interest income on funds invested, changes in the fair value of financial assets at fair value through profit or loss, changes in fair value of derivative instruments and foreign currency gains. Interest income is recognized as it accrues using the effective interest method. Financing expenses are comprised of changes in fair value of derivative instruments, as well as changes in the fair value of financial assets at fair value through profit or loss and foreign currency losses. In the statements of cash flows, interest received and interest paid are presented as part of cash flows from operating activities. Foreign currency gains and losses are reported on a net basis. M. Taxes on income Taxes on income are comprised of current and deferred tax. Current tax is the expected tax payable (or receivable) on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date. Deferred tax is recognized with respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. A deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which that can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. A provision for uncertain tax positions, including additional tax and interest expenses, is recognized when it is more probable than not that the Group will have to use its economic resources to pay the obligation. Tax benefit arising from tax deduction on exercise of share options is recognized in statement of profit or loss to the extent of the cumulative remuneration expense recognized. Any excess benefit is recognized directly in equity. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity. N. Loss per share The Group presents basic and diluted loss per share data for its ordinary shares. Basic loss per share is calculated by dividing the loss attributable to ordinary shareholders of the Group by the weighted average number of ordinary shares outstanding during the year. Diluted loss per share is determined by adjusting the loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares, which are comprised of share options and share options granted to employees and warrants held by investors. O. Comprehensive income The Group has no comprehensive income components other than net income or loss.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2017
Cash and cash equivalents [abstract]
Cash and Cash Equivalents	Note 4 - Cash and Cash Equivalents December 31 2017 2016 USD thousands USD thousands Current balances in banks 31,072 14,784 Deposits held at financial institutions, with original maturity periods of up to three months 15,304 170 46,376 14,954 The deposits outstanding, as of December 31, 2017, bear annual interest of -0.01%1.47%. The Group’s exposure to credit, interest rate and currency risks and a sensitivity analysis for financial assets are disclosed in Note 26.

Investments

Investments	12 Months Ended
	Dec. 31, 2017
Disclosure of associates [abstract]
Investments	Note 5 - Investments Breakdown according to type of investment December 31 2017 2016 USD thousands USD thousands Short-term investments Deposits held at financial institutions, in USD (*)56,693 (*)37,849 Investments in marketable securities Mutual funds 15 13 56,708 37,862 Long-term investments Deposits held at financial institutions, in USD 5,171 9,017 The deposits outstanding, as of December 31, 2017, bear annual interest of 0.86%-2.00%. The Group’s exposure to credit, interest rate and currency risks, and a sensitivity analysis for financial assets are disclosed in Note 26. (*) Including restricted cash in the amount of USD 1,107 thousand and USD 1,331 thousand for bank guarantees, as of December 31, 2017 and December 31, 2016, respectively.

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2017
Disclosure of other current assets [Abstract]
Other Current Assets	Note 6 - December 31 2017 2016 USD thousands USD thousands Institutions 1,027 1,127 Prepaid expenses 421 254 Interest receivable 271 171 Advances to suppliers 32 1 Other receivables 303 175 2,054 1,728 The Group’s exposure to credit and currency risk is disclosed in Note 26.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2017
Classes of current inventories [abstract]
Inventory	Note 7 - Inventory December 31 2017 2016 USD thousands USD thousands Raw materials and spare parts 3,199 1,634 Work in progress 187 232 Finished goods 4,478 2,849 7,864 4,715

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2017
Disclosure of detailed information about property, plant and equipment [abstract]
Property and Equipment, net	Note 8 - Property and Equipment, net Office Machinery furniture Computers Motor and and Leasehold and vehicles equipment equipment improvements equipment Total USD thousands Cost Balance as of January 1, 2017 - 3,613 214 820 1,495 6,142 Additions - 1,601 87 170 264 2,122 Disposals (*) - (313 ) - - (81 ) (394 ) Balance as of December 31, 2017 - 4,901 301 990 1,678 7,870 Balance as of January 1, 2016 33 1,880 193 301 1,236 3,643 Additions - 1,765 31 828 313 2,937 Disposals (33 ) (32 ) (10 ) (309 ) (54 ) (438 ) Balance as of December 31, 2016 - 3,613 214 820 1,495 6,142 Depreciation Balance as of January 1, 2017 - 1,345 67 3 1,112 2,527 Depreciation for the year - 771 19 185 214 1,189 Disposals (*) - (88 ) - - (81 ) (169 ) Balance as of December 31, 2017 - 2,028 86 188 1,245 3,547 Balance as of January 1, 2016 26 954 64 188 979 2,211 Depreciation for the year 3 423 13 124 185 748 Disposals (29 ) (32 ) (10 ) (309 ) (52 ) (432 ) Balance as of December 31, 2016 - 1,345 67 3 1,112 2,527 Carrying amount Balance as of January 1, 2016 7 926 129 113 257 1,432 Balance as of December 31, 2016 - 2,268 147 817 383 3,615 Balance as of December 31, 2017 - 2,873 215 802 433 4,323 (*) In 2017 the Company sold two Mazor X systems that were classified as fixed assets to one of its customers. The depreciated value of the two systems was USD 225 thousand.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2017
Disclosure of detailed information about intangible assets [abstract]
Intangible Assets	Note 9 - Intangible Assets Intangible assets include capitalized development costs relating to one of the Company’s products in accordance with the requirements of IAS 38, Intangible Assets During 2016 the Company capitalized development costs, as detailed below. In the years 2017 and 2015 the Company did not capitalize development costs. Presented hereunder is the movement in the carrying amount of intangible assets during the years 2017 and 2016: Capitalized development costs USD thousands Cost Balance as of December 31, 2017 and 2016 2,332 Amortization Balance as of December 31, 2016 74 Amortization for the year ended December 31, 2017 333 Balance as of December 31, 2017 407 Carrying amount December 31, 2016 2,258 December 31, 2017 1,925 Amortization The current amortization of development costs is recognized in cost of sales.

Other Current Liabilities

Other Current Liabilities	12 Months Ended
	Dec. 31, 2017
Other Current Liabilities Schedule Of Other Current Liabilities Details
Other Current Liabilities	Note 10 - Other Current Liabilities A. Deferred income December 31 2017 2016 USD thousands USD thousands Other deferred income 3,471 2,197 Deferred income relating to trade-in arrangements - 1,834 3,471 4,031 B. Other current liabilities December 31 2017 2016 USD thousands USD thousands Salary and related liabilities 5,114 4,905 Accrued expenses 4,280 3,029 Institutions 234 300 Tax provision 8 8 Related parties* 76 45 Other 162 175 9,874 8,462 * See Note 21 - Related Parties, for additional information regarding transactions and balances with related parties. The Group’s exposure to currency and liquidity risks related to certain payables is disclosed in Note 26.

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2017
Disclosure of defined benefit plans [abstract]
Employee Benefits	Note 11 - Employee Benefits Employee benefits mostly include post-employment benefits for Israeli employees who are in the scope of Section 14 of the Israeli Severance Pay Law - 1963, that are accounted for as defined contribution plans. The Group also has immaterial defined benefit plans for which it deposits amounts in appropriate insurance policies . Such amounts Regarding short-term benefits see Note 10B - Other Current Liabilities. Regarding share-based payments see Note 23 - Share-Based Payments. Post-employment benefit plans - defined contribution plan For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Amount recognized as expense in respect of defined contribution plan 462 368 243

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2017
Disclosure of taxes on income [Abstract]
Taxes on Income	Note 12 - Taxes on Income A. Details regarding the tax environment of the Group (1) Corporate tax rate (a) Presented hereunder are the Israeli tax rates in the years 2015-2017: 2015 - 26.5% 2016 - 25% 2017 – 24% Capital gains derived by an Israeli company are subject to the same tax rate. (b) On January 4, 2016, the Knesset plenum passed the Law for the Amendment of the Income Tax Ordinance (Amendment 216) - 2016, by which, inter alia, the corporate tax rate would be reduced by 1.5% to a rate of 25% as from January 1, 2016. Furthermore, on December 22, 2016, the Knesset plenum passed the Economic Efficiency Law (Legislative Amendments for Achieving Budget Objectives in the Years 2017 and 2018) - 2016, by which, inter alia, the corporate tax rate would be reduced from 25% to 23% in two steps. The first step will be to a rate of 24% as from January 2017 and the second step will be to a rate of 23% as from January 2018. (2) Benefits under the Israeli Law for the Encouragement of Capital Investments - 1959 (hereinafter - “the Law”) (a) In April 2004, the Company was granted “Approved Enterprise” status in accordance with the Law with respect to a plan to construct a plant in Caesarea, Israel for the manufacture of systems for assisting and guiding complex surgical procedures. In February 2007, the aforementioned approved enterprise status was revoked at the request of the Company, and in respect of an expansion of its plant in the Caesarea industrial park it was granted “Beneficiary Enterprise” status per the definition of this term in the Law. In accordance with this status, the Company will be entitled to the tax benefits provided by the Law with respect to income of the beneficiary enterprise from productive activity. Income of the beneficiary enterprise from productive activity will be exempt from corporate corporate corporate (2) Benefits under the Israeli Law for the Encouragement of Capital Investments - 1959 (hereinafter - “the Law”) (cont’d) (b) On December 29, 2010, the Knesset approved the Economic Policy Law for 2011-2012, which includes an amendment to the Law for the Encouragement of Capital Investments - 1959 (hereinafter - “the Amendment”). The Amendment is effective from January 1, 2011 and its provisions apply to preferred income derived or accrued in 2011 and thereafter by a preferred company, per the definition of these terms in the Amendment. Companies can choose not to be included in the scope of the amendment to the Encouragement Law and to stay in the scope of the law before its amendment until the end of the benefits period of its approved/beneficiary enterprise. The Amendment provides that only companies in Development Area A will be entitled to the grants track and that they will be entitled to receive benefits under this track and under the tax benefits track at the same time. In addition, the existing tax benefit tracks were eliminated (the tax exempt track, the “Ireland” track and the “Strategic” track) and two new tax tracks were introduced in their place, a preferred enterprise and a special preferred enterprise, which mainly provide a uniform and reduced tax rate for all the company’s income entitled to benefits. On August 5, 2013 the Knesset passed the Law for Changes in National Priorities (Legislative Amendments for Achieving Budget Objectives in the Years 2013 and 2014) - 2013, which raised the tax rates on preferred income as from the 2014 tax year as follows: 9% for Development Area A and 16% for the rest of the country. On December 21, 2016 the Knesset which reduced the tax rate on preferred income for a preferred enterprise in Development Area A from 9% to 7.5% as from 2017. The Amendment also provides that no tax will apply to a dividend distributed out of preferred income to a shareholder that is an Israeli resident company. A tax rate of 20% shall apply to a dividend distributed out of preferred income to an individual shareholder or foreign resident, subject to double taxation prevention treaties. The Company complies with . However, the Company Additional amendments to the Investment Law became effective in January 2017 (the “2017 Amendment”). Under the 2017 Amendment, and provided the conditions stipulated therein are met, income derived by Preferred Companies from ‘Preferred Technological Enterprises’ (or “PTE”, as defined in the 2017 Amendment), would be subject to reduced corporate tax rates of 7.5% in Development Zone A and 12% elsewhere, or 6% in case of a ‘Special Preferred Technological Enterprise’ (as defined in the 2017 Amendment). A Preferred Company distributing dividends from income derived from its PTE or Special Preferred Technological Enterprise, would subject the recipient to a 20% tax (or lower, if so provided under an applicable tax treaty). The 2017 Amendment further provides that, in certain circumstances, a dividend distributed to a corporate shareholder who is not an Israeli resident for tax purposes, would be subject to a 4% tax (inter alia, if the amount of foreign investors in the distributing company exceeds 90%). Such taxes would generally be withheld at source by the distributing company. (3) Benefits under the Law for the Encouragement of Industry (Taxes) The Company qualifies as “Industrial Companies” as defined in the Law for the Encouragement of Industry (Taxes) – 1969 and accordingly is (a) Higher rates of depreciation. (b) Amortization in three equal annual portions of issuance expenses when registering shares for trading as from the date the shares of the company were registered. (c) An 8-year period of amortization for patents and know-how serving in the development of the enterprise. (d) The possibility of submitting consolidated tax returns by companies in the same line of business. (4) Measurement of taxable income under the Income Tax (Inflationary Adjustments) Law, 1985 Since 2015 the Company maintains (5) Taxation of the subsidiary in the U.S. The tax rates applicable to the subsidiary incorporated in the U.S. are federal tax rate of 34% plus state tax of 0.75% to 9.99%, depending on the state. Furthermore, certain states in which the subsidiary operates have a minimum tax. Israel and the U.S. have a double tax avoidance treaty. According to the treaty, dividends and interest are subject to withholding tax of 12.5% and 17.5%, respectively. On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Act”), which among other provisions, reduced the U.S. corporate tax rate from 35% to 21%, effective January 1, 2018. The Company is of the . The deferred tax balances as at December 31, 2017 were calculated according to the new tax rate, at the tax rate expected to apply on the date of reversal B. Composition of income tax expense For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Current tax expense Current tax 23 265 97 Prior year taxes (50 ) - - Deferred tax expense ( benefit Changes in deferred tax assets\ liabilities in subsidiary (129 ) (221 ) 116 Total tax expense (benefit) (156 ) 44 213 C. Reconciliation between the theoretical tax on the pre-tax profit and the tax expense For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Loss before taxes on income (12,575 ) (18,624 ) (15,172 ) Primary tax rate of the Company 24 % 25 % 26.5 % Tax calculated according to the Company’s primary tax rate (3,018 ) (4,656 ) (4,021 ) Changes to tax in respect of: Different tax rate of foreign subsidiaries 122 94 54 Non-deductible expenses 1, 658 1,179 875 Tax losses and benefits for which deferred tax assets were not created 1, 077 3,583 3,290 Tax losses and benefits for which deferred Prior years taxes (50 ) - - Other differences 55 (156 ) 15 Income tax expense (benefit) (156 ) 44 213 D. Deferred tax assets and liabilities (1) The Company has recognized deferred tax assets and liabilities in respect of the following items: December 31 2017 2016 USD thousands USD thousands Property and equipment (44 ) (102 ) Tax losses and other temporary differences 431 360 Deferred tax assets 387 258 Deferred taxes in respect of the losses of the U.S. subsidiary were recognized, following the profitability of the U.S. subsidiary in recent years and convincing evidence that the U.S. subsidiary will experience sufficient taxable income in the near future and following the evaluation of the losses that more likely than not will be allowable under applicable tax laws. (2) Unrecognized deferred tax assets Deferred tax assets have not been recognized in respect of the following items: December 31 2017 2016 USD thousands USD thousands Deductible temporary differences, net 6,091 5,034 Capital tax losses 7, 461 7,486 Operating tax losses 114,345 92,089 The deductible temporary differences and tax losses incurred by the Israeli company do not expire under current tax legislation in Israel. The Group did not recognize deferred tax assets in respect of these items since it is not probable that future taxable income will be available against which the Group can use the benefits therefrom, other than a deferred tax asset in respect of losses and tax credits of the U.S. subsidiary that will probably be utilized. In general, the losses of the subsidiary in the U.S. can be used for up to a period of 20 years according to the tax laws of its state of incorporation. The utilization of the subsidiary’s tax losses has been limited to USD 207 thousand per year, by an “ownership change” under Section 382 of the Internal Revenue Code (the “Code”), which occurred during July 2009. An “ownership change” generally is a 50% increase in ownership over a three-year period by stockholders who directly or indirectly own at least 5% of the Company’s stock. The limitation applies to all tax losses existing at the time of the ownership change. On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Act”), which among other provisions, reduced the U.S. corporate tax rate from 35% to 21%, effective January 1, 2018. As of December 31, 2017, the Act did not have a material impact on the financial statements. The amount of benefits the Company may receive from the operating loss carry forwards for income tax purposes is further dependent, in part, upon the tax laws in effect, the future earnings of the Company, and other future events, such as additional changes in ownership, the effects of which cannot be determined. E. Carry-forward losses The Company has carry-forward operating tax losses and carry-forward capital tax losses of USD 96,307 The U.S. subsidiary has carry-forward operating tax losses of USD 19,882 F. Tax assessments Tax years up to and including the year ended 2012 are considered final for the Company and the U.S. subsidiary. At the date of approval of the financial statements tax years 2013-2016 are under tax assessment of the Israeli Tax Authorities.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2017
Disclosure of commitments [Abstract]
Commitments	Note 13 - Commitments A. The Company and the U.S. subsidiary have operating lease agreements with respect to the buildings they use. The agreements of the Company will end in June 2021.The agreement of the U.S. subsidiary ended in April 2018 and was extended in 2018 for the period through December 31, 2018. The Company provided a promissory note in the amount of USD 15 thousand and deposited as a lien USD 304 thousand as security for the building lease. The lease payments for buildings in Israel are linked to the CPI and for those in the U.S. are stated at the U.S. dollar. The minimum annual lease payments under the agreements are as follows: December 31, 2017 USD thousands 2018 713 2019 26 2020 626 2021 313 2,278 The lease payments amounted to USD 853 thousand in 2017 and USD 648 thousand in 2016. B. The Company leases motor vehicles under operating lease agreements for a period of 32 to 36 months. With regards to these agreements, the Company has deposited amounts as security for the future rent payments. As of the reporting date the balance of prepaid expenses on account of the lease of motor vehicles is USD 132 thousand (December 31, 2016 – USD 93 thousand). The deposits are linked to the CPI and do not bear interest. The minimum annual payments according to the agreements are as follows: December 31, 2017 USD thousands 2018 456 2019 333 2020 103 892 The lease motor vehicles payments amounted to USD 454 thousand in 2017 and USD 309 thousand in 2016. C. As of December 31, 2017, the Company has purchase obligations in the amount of USD 3,819 thousand (as of December 31, 2016: USD 5,590 thousand) which mainly represent outstanding purchase commitments for inventory components and R&D materials ordered in the normal course of business.

Revenues

Revenues	12 Months Ended
	Dec. 31, 2017
Revenue [abstract]
Revenues	Note 14 - Revenues For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Sales of systems 37,071 19,624 13,373 Sales of disposables 16,246 10,295 7,648 Services and other 11,630 6,460 5,075 64,947 36,379 26,096

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2017
Disclosure of operating segments [abstract]
Segment Reporting	Note 15 - Segment Reporting A. Information about reportable segments The Group has one reportable segment. B. Entity level disclosures (1) Major Customers Revenues from one customer of the Group represents approximately USD 14,400 thousand of the Group’s total revenue. In the years ended December 31, 2016, and December 31, 2015, there were no major customers. (2) Information on products and services The Group’s revenues from external parties in respect of each category of similar products and services are presented in Note 14. (3) Information on geographical areas For the year ended December 31, 2017 U.S.A. International Total USD in thousands Total revenues 59,525 5,422 64,947 For the year ended December 31, 2016 U.S.A. International Total USD in thousands Total revenues 30,716 5,663 36,379 For the year ended December 31, 2015 U.S.A. International Total USD in thousands Total revenues 20,271 5,825 26,096 * Virtually all of the Company’s long-lived assets are located in Israel.

Cost of Sales

Cost of Sales	12 Months Ended
	Dec. 31, 2017
Disclosure of cost of sales [Abstract]
Cost of Sales	Note 16 - Cost of Sales For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Materials and subcontractors 18,483 7,503 3,669 Salaries, wages and related expenses 2,732 1,474 1,264 Depreciation and amortization 871 418 193 Other manufacturing expenses 1,598 935 701 Total cost of sales 23,684 10,330 5,827

Research and Development Expens

Research and Development Expenses, net	12 Months Ended
	Dec. 31, 2017
Disclosure of research and development expenses [Abstract]
Research and Development Expenses, net	Note 17 - Research and Development Expenses, net For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Materials and subcontractors 2,037 2,444 2,690 Salaries, wages and related expenses 5,488 4,167 2,875 Depreciation 131 97 45 Patent registration expenses 135 208 106 Overhead 942 539 355 Other research and development expenses 386 613 253 9,119 8,068 6,324 Less: capitalized cost - (2,332 ) - co-development participation (927 ) - - Total research and development expenses 8,192 5,736 6,324

Selling and Marketing Expenses

Selling and Marketing Expenses	12 Months Ended
	Dec. 31, 2017
Disclosure of selling and marketing expenses [Abstract]
Selling and Marketing Expenses	Note 18 - Selling and Marketing Expenses For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Salaries, wages and related expenses 27,716 22,270 16,143 Consultation 2,926 2,439 1,834 Advertising, demonstrations and exhibitions 1,994 3,243 2,546 Travel expenses 4,627 3,814 2,696 Depreciation 451 259 213 Excise tax - - 308 Overhead 998 919 707 Other selling and marketing expenses 787 693 500 Total selling and marketing expenses 39,499 33,637 24,947

General and Administrative Expe

General and Administrative Expenses	12 Months Ended
	Dec. 31, 2017
Disclosure of general and administrative expenses [Abstract]
General and Administrative Expenses	Note 19 - General and Administrative Expenses For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Salaries, wages and related expenses 4,535 3,525 2,395 Professional services 1,802 1,510 1,271 Travel expenses 216 192 214 Overhead 445 203 133 Other general and administrative expenses 377 267 292 Total general and administrative expenses 7,375 5,697 4,305

Financing Income and Expenses

Financing Income and Expenses	12 Months Ended
	Dec. 31, 2017
Disclosure of financing income and expenses [Abstract]
Financing Income and Expenses	Note 20 - Financing Income and Expenses For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Interest income and net change in fair value of receivable interest 701 399 269 Net income from change in exchange rates 501 - - Hedging transactions 45 39 3 Financing income recognized in profit or loss 1,247 438 272 Net expenses from change in exchange rates - (10 ) (113 ) Other financing expenses (19 ) (31 ) (24 ) Financing expenses recognized in profit or loss (19 ) (41 ) (137 ) Net financing income 1,228 397 135

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2017
Disclosure of transactions between related parties [abstract]
Related Parties	Note 21 - Related Parties A. Key management personnel compensation (including directors) In addition to their salaries, the Group also provides non-cash benefits to directors and executive officers (such as a car, etc.), and contributes to post-employment plans on their behalf. Executive officers and directors also participate in the Company’s share option program (see Note 23 regarding share-based payments). Compensation to key management personnel (including one director) that are employed by the Group: For the year ended December 31 2017 2016 2015 Number USD Number of USD Number USD of people thousands people thousands of people thousands Employee benefits 11 3,270 9 2,752 9 2,092 Share-based payments 11 1,841 9 1,865 9 1,285 5,111 4,617 3,377 Compensation to directors: For the year ended December 31 2017 2016 2015 Number USD Number of USD Number USD of people thousands people thousands of people thousands Total compensation to directors employed by the Company* 1 387 1 199 1 187 Compensation to independent directors** 4 753 5 354 4 423 * Including share-based payments in the amount of USD 255 thousand, USD 82 thousand and USD 78 thousand in 2017, 2016 and 2015, respectively. ** Including share-based payments in the amount of USD 519 thousand, USD 194 thousand and USD 287 thousand in 2017, 2016 and 2015, respectively. B. Engagements between the Company and related parties (1) On 8, 2015 and July 19, 2016, the Company’s general meeting of shareholders approved additional share-based compensation to the CEO – For further details, see Note 23(C). (2) On July 19, 2016, the Company’s shareholders approved an amendment to the employment terms of the CEO, based on the compensation committee and the Board of Directors recommendation, such that the CEO salary, effective March 1, 2016, has been updated to NIS 80 thousand per month. On the same date, the Company’s shareholders (3) On November 28, 2016, the Company’s shareholders approved share-based compensation to all of the directors - For further details see Note 23(C). (4) On December 27, 2017, the Company’s shareholders approved an amendment to the employment terms of the CEO, based on the compensation committee and the Board of Directors recommendation, such that the CEO salary, effective January 1, 2018, has been updated to NIS 90 thousand per month.

Equity

Equity	12 Months Ended
	Dec. 31, 2017
Disclosure of classes of share capital [abstract]
Equity	Note 22 - Equity A. Share capital December 31 Number of Ordinary shares 2017 2016 Thousands of shares of NIS 0.01 par value Issued and paid-in share capital as of January 1 47,619 42,352 Issuance of share capital to investors , see note 22C(2) 2,080 3,917 Exercise of warrants by investors , see note 22C(1) - 134 Exercise of share options by employees , see note 23 2,383 1,216 Issued and paid-in share capital as of December 31 52,082 47,619 Authorized share capital 75,000 75,000 The holders of ordinary shares are entitled to receive dividends, if declared, and are entitled to one vote per share at general meetings of the Company. B. Warrants held by investors December 31 Number of options 2017 2016 Thousands of options and warrants of NIS 0.01 par value Number of outstanding options and warrants as of January 1 - 134 Issued during the period 2,420 (*) - Exercised during the period - (134 ) Number of outstanding options and warrants as of December 31 2,420 - (*) The amount of 2,420 thousand warrants represent the number of shares to be issued, pursuant to exercise of 1,210 thousand warrants issued to Medtronic, in connection with a private issuance in 2017. For further details see note 22(C)(2). C. Issuances of share capital (1) Private placement - 2011 As part of private placement that took place in 2011, the Company allotted options, as to the following: (1) The Phoenix Insurance Company Ltd., for itself and for other companies of the Phoenix Group (together Phoenix), on the basis of an internal distribution agreed to by the parties, 2,000,000 ordinary shares of the Company with a par value of NIS 0.01, and 800,000 non-marketable options that will not be listed for trading and are exercisable into 800,000 ordinary shares of the Company with a par value of NIS 0.01 over a period of five years from the date of their allotment at an exercise price of NIS 14 (approximately USD 3.88) per option. (2) Leader Issuances (1993) Ltd. 421,053 ordinary shares of the Company with a par value of NIS 0.01, and 168,421 non-marketable options that will not be listed for trading and are exercisable into 168,421 ordinary shares of the Company with a par value of NIS 0.01 over a period of five years from the date of closing at an exercise price of NIS 14 (approximately USD 3.88) per option. According to the binomial model, on the grant date the fair value of each one of the options is USD 1.02 and the fair value of all the options allotted to the offerees is USD 995 thousand. The Company split the overall consideration from the issuance pro rata to the fair value of the equity instruments that were issued so that an amount of USD 825 thousand was recognized as proceeds from options and an amount of USD 5,561 thousand was included in share capital and premium. On February 21, 2016 following exercise of the warrants, the Company issued an aggregate of 134,421 Ordinary Shares for total aggregate consideration of NIS 1,882 thousand (approximately USD 481 thousand). (2) Private issuance - 2016-2017 On May 16, 2016, the Company entered into two strategic agreements with Medtronic. One agreement is a two-phase Exclusive Lead Sharing and Distribution Agreement which provides for co-promotion, co-development and, upon meeting certain milestones, potential global distribution of the Mazor X System. The second agreement is a Purchase Agreement which provides for a three-tranche equity investment by Medtronic in Mazor. On May 25, 2016, the Company issued to Medtronic 1,042,992 ADSs, representing 2,085,984 ordinary shares, par value NIS 0.01, at a price of USD 11.42 per ADS, bringing total gross proceeds from the issuance to USD 11,911 thousands before deducting issuance expenses payable by the Company. The total issuance expenses amounted to approximately USD 265 thousands. On August 11, 2016, the Company issued to Medtronic 915,692 ADSs, representing 1,831,384 ordinary shares, par value NIS 0.01, the at a price of USD 21.84 per ADS, bringing total gross proceeds from the issuance to USD 20,000 thousands before deducting issuance expenses payable by the Company. On September 11, 2017, the Company issued to Medtronic 1,040,106 ADSs, representing 2,080,212 ordinary shares, par value NIS 0.01, the at a price of USD 38.46 per ADS, bringing total gross proceeds from the issuance to USD 40,000 thousands before deducting issuance expenses payable by the Company. The Company also issued to Medtronic warrants to purchase an additional 1 , For further details on the agreement and the potential fourth investment tranche (by exercise of warrants),

Share-Based Payments

Share-Based Payments	12 Months Ended
	Dec. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Share-Based Payments	Note 23 - Share-Based Payments A. Grant of share options to employees and directors of the Company The Company regularly compensates its employees, directors, consultants and other service providers by means of options to purchase ordinary shares of the Company. As of December 31, 2017, the Company has outstanding options to purchase 4,780,317 ordinary shares of the Company with a par value of NIS 0.01. All of the grants are equity grants. As of that date, options to purchase 1,595,666 ordinary shares are exercisable. B. As of December 31, 2017, the Company has 2 stock option plans for employees, directors, consultants and other service providers of the Group (the “2003 Plan” and the “2011 Plan”). No further grants may be made under the 2003 Plan. On May 30, 2011, the Company’s Board of Directors approved the 2011 Plan which allows for grants to the Company’s employees, directors, consultants and other service providers of the Group. The Company will be able to grant up to 9,262,529 options at any time throughout a period of 10 years from the date of approval of the 2011 Plan according to the terms of the plan. As of December 31, 2017, there are 567,684 additional options available for grant under the 2011 Plan. C. The number and weighted average exercise prices of share options are as follows: Weighted Weighted average Weighted average exercise Number of average Number of exercise Number of price* options exercise price* options price* options 2017 2017 2016 2016 2015 2015 US dollars US dollars US dollars Balance at January 1 6.45 6,668,441 5.43 5,531,623 5.43 4,540,158 Forfeited during the year 7.99 (387,447 ) 6.83 (235,718 ) 7.09 (364,408 ) Exercised during the year 6.27 (2,382,927 ) 3.59 (1,216,115 ) 1.70 (218,277 ) Granted during the year 19.15 882,250 7.04 2,588,651 6.76 1,574,150 Outstanding at December 31 9.76 4,780,317 6.45 6,668,441 5.43 5,531,623 Exercisable at December 31 7.68 1,595,666 5.19 1,882,267 2.91 1,949,459 * The actual With respect to options granted to related parties, see Note 21 - Related Parties The average selling price of shares issued, pursuant to exercise of options was NIS 80.15 and NIS 42.02 for the years ended December 31, 2017 and 2016 D . Total expense recognized as salary expense for years ended December 31, 2017 are USD 6,370 thousand (USD 4,439 thousand and USD 3,091 thousand for years ended December 31, 2016 and 2015, respectively). E. The fair value of share options granted to employees, directors, consultants and other service providers is measured using the binomial model. Measurement inputs include the share price on the measurement date, the exercise price of the instrument, expected volatility (based on the historical volatility), the expected life span of the options taking in consideration certain acceleration terms, and the risk-free interest rate (based on government debentures). Service and non-market performance conditions attached to the transactions are not taken into account in determining fair value. The parameters used in the measurement of the fair value Share price Contractual that served Total Vesting life of the Average as a basis fair value of Grant date Number of Period options Interest Expected exercise for pricing the benefit on DD/MM/YEAR Offerees instruments (Years) (Years) rate Volatility** price* the option* the grant date % % USD USD USD thousands 29/01/2015 Officer and consultant 110,000 2-4 7 1.5 48.61 5.83 5.35 268 15/02/2015 Employees 104,250 2-4 7 1.65 48.65 5.86 5.86 269 26/02/2015 Officer 100,000 1.5-3.5 7 1.44 48.69 6.28 5.82 261 04/05/2015 Employees and consultant 144,500 2-4 7 1.36 48.88 6.44 6.44 440 15/07/2015 Officers, employees and consultants 941,900 2-4 7 2.03 48.84 7.17 7.17 3,269 08/10/2015 CEO 60,000 2-4 6.77 1.7 49.37 7.01 5.75 153 29/10/2015 Employees 113,500 2-4 7 1.64 48.92 5.81 5.56 294 14/02/2016 Employees and consultants 112,500 2-4 7 1.48 49.25 5.32 4.35 216 02/05/2016 Employee 42,500 2-4 7 1.52 48.14 6.06 6.06 120 10/05/2016 Consultant 25,000 2-4 7 1.47 48.10 5.91 5.58 68 18/05/2016 Officers and employees 1,424,327 2-4 1.95-7.00 0.24-1.5 44.22-48.72 5.80 5.35 3,474 19/07/2016 CEO 386,574 2-4 6.77 1.43 46.83 5.77 9.98 2,333 28/07/2016 Officer, Employees and consultant 116,900 2-4 7 0.18-1.42 46.06-46.73 9.79 9.79 531 06/11/2016 Employees 240,850 2-4 1.48-7.00 0.22-1.64 45.94-46.63 11.57 11.06 1,209 28/11/2016 Directors 240,000 1-3 6.88-7.00 1.90-1.94 46.60-46.62 11.71 11.40 1,266 14/02/2017 Employees 201,500 2-4 1.21-7.00 0.20-1.95 46.34-46.38 11.52 10.93 1,009 04/05/2017 Employees and Consultant 74,500 2-4 0.99-7.00 0.17-1.84 46.68-49.97 17.95 17.95 642 15/06/2017 Employees and Officers 245,750 2-4 0.87-7.00 0.11-1.68 46.76-48.25 19.56 17.62 1,936 23/08/2017 Employees and Consultants 125,500 2-4 7.00 1.26 47.22 19.39 19.18 1,120 07/09/2017 Consultant 50,000 2 7.00 1.33 47.35 23.60 23.60 582 03/10/2017 Officer 135,000 2-4 7.00 1.40 47.34 25.04 25.04 1,611 05/11/2017 Consultant 50,000 2-4 7.00 1.37 47.70 28.75 28.75 714 * The exercise price and share price are denominated in NIS and are re-measured using historic exchange rates. ** Expected volatility is estimated by considering historic share price volatility of the Company. The risk-free interest rate was determined on the basis of non-interest bearing NIS-denominated Government debentures with a remaining life equal to the expected term of the options.

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2017
Earnings per share [abstract]
Loss Per Share	Note 24 - Loss Per Share A. Basic loss per share The calculation of basic loss per share for the years ended December 31, 2017, 2016 and 2015 was based on the loss attributable to ordinary shareholders divided by a weighted average number of ordinary shares outstanding calculated as follows: (1) Loss attributable to ordinary shareholders For the year ended December 31 2017 2016 2015 USD Thousands USD Thousands USD Thousands Loss for the year 12,419 18,668 15,385 (2) Weighted For the year ended December 31 2017 2016 2015 USD Thousands USD Thousands USD Thousands Balance as of January 1 47,619 42,352 42,133 Effect of shares issued during the year 1,535 2,529 151 Weighted average number of ordinary shares used to calculate basic loss per share 49,154 44,881 42,284 B. Diluted loss per share At December 31, 2017, an amount of

Financial Risk Management

Financial Risk Management	12 Months Ended
	Dec. 31, 2017
Disclosure of detailed information about financial instruments [abstract]
Financial Risk Management	Note 25 - Financial Risk Management A. Overview The Group has exposure to the following risks from its use of financial instruments: — redit risk; — iquidity risk; and — arket risk (including currency, interest and other market price risks). B. Risk management framework This note presents information about the Group’s exposure to each of the above risks, and the Group’s objectives, policies and processes for measuring and managing risk. Further quantitative disclosures are included throughout these consolidated financial statements. The Board of Directors has overall responsibility for the establishment and oversight of the Group’s risk management framework. The Group’s risk management policies are established to identify and analyze the risks faced by the Group, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Group’s activities. The Group, through its training and management standards and procedures, aims to develop a disciplined and constructive control environment in which all employees understand their roles and obligations. The Board of Directors oversees how management monitors compliance with the Group’s risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Group. The Board of Directors is assisted in its oversight role by Internal Audit. Internal Audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the Audit Committee. C. Credit risk Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Group’s trade and other receivables, as well as from cash and cash equivalents and investment in marketable securities. Trade and other receivables The Group’s exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the Group’s customer base, including the default risk of the industry and country in which customers operate have only a small effect on the credit risk. The Group establishes a provision for doubtful debts that represents its estimate of incurred losses in respect of trade and other receivables. The main components of this provision are specific loss components that relate to individually significant exposures. Cash and cash equivalents and Investments The Group limits its exposure to credit risk by holding cash and investing only in bank deposits and debentures and only with counterparties that have a credit rating of at least A+ according to the rating accepted in Israel. Given these high credit ratings, management does not expect any counterparty to fail to meet its obligations. D. Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty in meeting its financial obligations when due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses. E. Market risks Market risk is the risk that changes in market prices, such as foreign exchange rates, the CPI, interest rates and equity prices will affect the Group’s income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return. Currency risk The Group is exposed to currency risk arising primarily from exposure to NIS The Company engages in derivative instruments transactions, such as options and forward contracts, for the purposes of hedging the Company’s NIS payments to local suppliers and for salaries in Israel. The Company’s hedging transactions are aimed to decrease a certain portion of the financial exposure risk of fluctuations in the exchange rates of the Company’s operating currency, which is the U.S. dollar against the NIS. Interest rate risk The Group is exposed to changes in interest rates, primarily possible changes in the risk-free market interest rate which may have an effect on the fair value of the Group’s short and long-term investments.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2017
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments	Note 26 - Financial Instruments A. Credit Risk (1) Exposure to credit risk The maximum exposure to credit risk for cash and cash equivalents, deposits, short-term investments, trade receivables and long-term investments at the reporting date by type of counterparty was: December 31 2017 2016 Carrying Carrying amount amount USD thousands Cash and cash equivalents 46,376 14,954 Mutual funds 15 13 Short-term investments - bank deposits 56,693 37,849 Trade receivables 6,056 8,225 Other current assets 271 171 Long-term investments - bank deposits 5,171 9,017 114,582 70,229 The maximum exposure to credit risk for trade receivables at the reporting date by geographic region was as follows: December 31 2017 2016 USD thousands Israel 819 29 United States 4,644 7,503 Asia Pacific 75 497 Rest of the world 518 196 6,056 8,225 (2) Aging of debts and impairment losses The aging of trade receivables at the reporting date was: December 31 2017 2016 USD thousands Not past due 5,610 7,986 Past due 0-30 days 417 215 Past due 31-60 days 19 24 Past due 61-90 days 5 - Past due over 90 days 5 - 6,056 8,225 As of December 31, 2017 and 2016, the Company did not have an allowance for doubtful accounts. B. Liquidity risk All outstanding liabilities at December 31, 2017 and 2016 are to be paid within 6 months. C. Market risk (1) Linkage and foreign currency risks The Group’s exposure to linkage and foreign currency risk was as follows based on notional amounts: December 31, 2017 New Israeli Shekels Unlinked CPI Linked CPI US dollar Euro Non - monetary Total USD thousands Current Assets Cash and cash equivalents 9,977 - 35,812 587 - 46,376 Short-term investments 15 - 56,693 - - 56,708 Trade receivables 223 - 4,719 518 - 5,460 Other current assets 974 - 422 - 658 2,054 Inventory - - - - 7,864 7,864 Total current assets 11,189 - 97,646 1,105 8,522 118,462 Other non-current assets - 132 - - 387 519 Trade receivables 596 - - - - 596 Property and equipment, net - - - - 4,323 4,323 Intangible assets, net - - - - 1,925 1,925 Long-term investments - - 5,171 - - 5,171 Total assets 11,785 132 102,817 1,105 15,157 130,996 Current Liabilities Trade payables 1,275 - 2,199 - - 3,474 Deferred revenue - - - - 3,471 3,471 Other current liabilities 3,560 - 6,028 24 262 9,874 Total current liabilities 4,835 - 8,227 24 3,733 16,819 Employee benefits - - - - 414 414 Total liabilities 4,835 - 8,227 24 4,147 17,233 Total balance, net 6,950 132 94,590 1,081 11,010 113,763 December 31, 2016 New Israeli Shekels Unlinked CPI Linked CPI US dollar Euro Non- Total Current Assets USD thousands Cash and cash equivalents 2,300 - 11,923 731 - 14,954 Short-term investments 287 - 37,575 - - 37,862 Trade receivables 29 - 8,000 196 - 8,225 Other current assets 977 - 231 - 520 1,728 Inventory - - - - 4,715 4,715 Total current assets 3,593 - 57,729 927 5,235 67,484 Other non-current assets - 93 - - 258 351 Property and equipment, net - - - - 3,615 3,615 Intangible assets, net - - - - 2,258 2,258 Long-term investments - - 9,017 - - 9,017 Total assets 3,593 93 66,746 927 11,366 82,725 Current Liabilities Trade payables 1,615 - 3,264 139 - 5,018 Deferred revenue - - - - 4,031 4,031 Other current liabilities 2,676 - 5,440 18 328 8,462 Total current liabilities 4,291 - 8,704 157 4,359 17,511 Employee benefits - - - - 325 325 Total liabilities 4,291 - 8,704 157 4,684 17,836 Total balance, net (698 ) 93 58,042 770 6,682 64,889 Information regarding the CPI and significant exchange rates: For the year ended December 31, For the year ended December 31, 2017 2016 2015 2017 2016 2015 % of change Spot price of 1 USD at the reporting date 1 NIS 10.9 1.5 (0.3 ) 0.2884 0.2601 0.2563 1 Euro 13.9 (3.4 ) (10.4 ) 1.1978 1.0517 1.0884 CPI in points * 0.4 (0.2 ) (1.0 ) 113.05 112.60 112.82 * According to an average basis of 2008 The Group’s exposure to linkage and foreign currency risk in respect of derivatives is as follows: Currency/ Currency/ linkage linkage Amount Amount Date of receivable payable receivable payable Expiration Fair value NIS thousands USD thousands USD thousands December 31, 2017 Instruments not accounted for as hedging: Buy put options NIS USD 1,500 435 Jan-March 2018 3.6 Sell call options NIS USD 1,500 414 Jan-March 2018 (0.4 ) 3.2 December 31, 2016 Instruments not accounted for as hedging: Forward NIS USD 4,000 (1,039 ) Jan-March 2017 2 2 (2) Interest rate risk At the reporting date the interest rate profile of the Group’s interest-bearing financial instruments was as follows: December 31 2017 2016 Carrying Carrying amount amount USD thousands USD thousands Fixed rate instruments Deposits held at financial institutions, with original maturity periods of up to three months 15,304 170 Short-term investments 56,693 37,849 Long-term investments 5,171 9,017 77,168 47,036 Variable rate instruments Mutual funds 15 13 15 13 D. Fair value Fair value hierarchy 1. As of December 31, 2017, and 2016, the marketable securities in the amount of USD 15 thousand and USD 13 thousand, respectively held for trading are presented at fair value through profit or loss. The fair value is determined on the basis of quoted prices (unadjusted) in active markets for identical instruments (level 1). 2. As of December 31, 2017, derivative financial instruments classified as an asset in the amount of USD 3 thousand (As of December 31, 2016 - an asset of USD 2 thousand) are presented at fair value and changes recognized in the profit or loss statement. The fair value was valued utilizing market observable inputs (level 2). The fair value of these derivative financial instruments is measured based on observable market data, such as spot rate, yield curves and exchange rate volatility, as of the fair value calculation date.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent Events	Note 27 - Subsequent Events Through April 30, 2018, the Company issued an aggregate of 573,608 ordinary shares in connection with the exercise of options granted to employees under the 2003 Plan and 2011 Plan for a total consideration of NIS 14,453 thousand (approximately USD 4,126 thousand).

Significant Accounting Polici33

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Disclosure of significant accounting policies [Abstract]
Basis of consolidation	A. Basis of consolidation (1) Subsidiaries Subsidiaries are entities controlled by the Group. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. (2) Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements. Unrealized losses are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment.
Foreign currency transactions	B. Foreign currency transactions Transactions in foreign currencies are translated to the respective functional currencies of Group entities at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the year, adjusted for effective interest and payments during the year, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period. Foreign currency differences arising on translation are recognized in profit or loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.
Financial instruments	C. Financial instruments (1) Non-derivative financial assets Initial recognition of financial assets The Group initially recognizes loans, receivables and deposits on the date that they are originated. All other financial assets acquired in a regular way purchase, including assets designated at fair value through profit or loss, are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument (i.e., on the date the Group undertook to purchase or sell the asset). Non-derivative financial instruments comprise investments in marketable securities, deposits, trade and other receivables, and cash and cash equivalents. De-recognition of financial assets Financial assets are de-recognized when the Group’s contractual rights to the cash flows from the asset expire, or when the Group transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred. Any interest in transferred financial assets that is created or retained by the Group is recognized as a separate asset or liability. Regular way sales of financial assets are recognized, or de-recognized, on the trade date, which is the date that the Company undertook to purchase, or sell the assets. See (2) hereunder regarding the offset of financial assets and financial liabilities. The Group classifies its financial assets according to the following categories: Financial assets at fair value through profit or loss A financial asset is classified at fair value through profit or loss, if it is classified as held for trading. Attributable transaction costs are recognized in profit or loss as incurred. Financial assets at fair value through profit or loss are measured at fair value, and changes therein are recognized in profit or loss. Financial assets held for trading are comprised mainly of investments in marketable securities. Loans and receivables Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are recognized initially at fair value plus any direct attributable transaction costs. Subsequent to initial recognition, loans and receivables are measured at amortized cost using the effective interest method, less any impairment losses. Loans and receivables are comprised of trade receivables, deposits, other accounts receivable and cash and cash equivalents. Cash and cash equivalents are comprised of cash balances available for immediate use and call deposits. Cash equivalents are comprised of short-term highly liquid investments (with original maturities of three months or less) that are readily convertible into known amounts of cash and are not exposed to significant risks of change in value. (2) Non-derivative financial liabilities Financial liabilities are recognized initially on the trade date, at which the Group becomes a party to the contractual provisions of the instrument. Financial liabilities are de-recognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged or cancelled. Financial liabilities are recognized initially at fair value less any directly attributable transaction costs. Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Non-derivative financial liabilities comprise of, trade and other accounts payable. Financial assets and liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Group currently has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. (3) CPI-linked assets and liabilities that are not measured at fair value The value of CPI-linked financial assets and liabilities, which are not measured at fair value, is revalued every period in accordance with the actual increase/decrease in the CPI. (4) Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized as a deduction from equity. (5) Share options and warrants Receipts in respect of share options are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price.
Property and Equipment	D. Property and Equipment (1) Recognition and measurement Property and equipment Cost includes expenditure that is directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and direct labor, any other costs directly attributable to bringing the assets to a working condition for their intended use. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment. Spare parts, servicing equipment and stand-by equipment are to be classified as fixed assets when they meet the definition of fixed assets in IAS 16, and are otherwise to be classified as inventory. Gains and losses on disposal of property and equipment are determined by comparing the net proceeds from disposal with the carrying amount of the asset, and are recognized net within the relevant line item in profit or loss. (2) Subsequent costs The cost of replacing part of a property and equipment asset item is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Group and its cost can be measured reliably. The carrying amount of the replaced part is de-recognized. The costs of day-to-day servicing are recognized in profit or loss as incurred. (3) Depreciation Depreciation is a systematic allocation of the depreciable amount of an asset over its useful life. The depreciable amount is the cost of the asset, or other amount substituted for cost. An asset is depreciated from the date it is ready for use, meaning the date it reaches the location and condition required for it to operate in the manner intended by management. Depreciation is recognized in profit or loss on a straight-line basis over the estimated useful lives of the property and equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows: Computers and equipment 3 years Machinery and equipment 3-10 years Motor vehicles 7 years Office furniture and equipment 6-17 years Leasehold improvements The shorter of the lease term and the useful life Depreciation methods and useful lives are reviewed at each financial year-end and adjusted, if appropriate.
Intangible assets	E. Intangible assets (1) Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involve plans or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if: · development costs can be measured reliably; · the product or process is technically and commercially feasible; · future economic benefits are probable; and · the Group intends to and has sufficient resources to complete development and to use or sell the asset. With regard to some of the Company’s products, technical feasibility may occur only after the Company receives approval from the U.S. Food and Drug Administration (the FDA). Sometimes the costs incurred between the successful completion of the product’s development and successful trials, and the time the product is ready for sale are immaterial, so that in reality all of the development costs might be recognized in profit or loss, as incurred. Any capitalized expenditure includes the cost of materials, direct labor and other related costs that are directly attributable to developing the asset for its intended use. Other development expenditures are recognized in profit or loss as incurred. In subsequent periods, capitalized development expenditure will be measured at cost less accumulated amortization and accumulated impairment losses. (2) Subsequent expenditure Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated brands, is recognized in profit or loss, as incurred. (3) Amortization Amortization is a systematic allocation of the amortizable amount of an intangible asset over its useful life. The amortizable amount is the cost of the asset. Amortization is recognized in profit or loss, on a straight-line basis over the estimated useful lives of the intangible assets, from the date they are available for use, since these methods most closely reflect the expected pattern of consumption of the future economic benefits embodied in each asset. Management estimates the useful life of the capitalized development costs as 7 years. Amortization methods and useful lives are reviewed at each reporting date and adjusted if appropriate.
Inventory	F. Inventory Inventory is measured at the lower of cost and net realizable value. The cost of inventory is based on the moving average method, and includes expenditure incurred in acquiring the inventory and the costs incurred in bringing it to its existing location and condition. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. Management regularly evaluates the necessity of provisions for obsolescence, which may result from excess, slow-moving or obsolete inventories.
Impairment	G. Impairment (1) Non-derivative financial assets A financial asset not carried at fair value through profit or loss is tested for impairment when objective evidence indicates that one or more events had a negative effect on the estimated future cash flows of the asset. Objective evidence that financial assets are impaired may include: • default by a debtor; • indications that a debtor or issuer will enter bankruptcy; or • observable data indicating a measurable decrease in the cash flow expected from a group of financial assets. An impairment loss is reversed if the reversal can be related objectively to an event occurring after the recognition of the impairment loss. For financial assets measured at amortized cost the reversal is recognized in profit or loss. (2) Non-financial assets The carrying amounts of the Group’s non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its net selling price (fair value less costs to sell the asset). In assessing value in use, the estimated future cash flows are discounted to their present value using a discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or cash-generating unit, for which the estimated future cash flows from the asset or cash-generating unit were not adjusted. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets. An impairment loss is recognized if the carrying amount of an asset or its cash-generating unit exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss. Impairment losses recognized in respect of cash-generating units are allocated to reduce the carrying amounts of each of the assets in the cash-generating unit on a pro rata basis. Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized initially.
Employee benefits	H. Employee benefits (1) Post-employment benefits Most of the Group’s Israeli employees are subject to Section 14 of the Israeli Severance Pay Law - 1963 and therefore substantially all of the post-employment plans of the Group are classified as defined contribution plans. Defined contribution plans Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which services are rendered by employees. Long-term benefits are presented on a discounted basis and are immaterial to the financial statements. (2) Short-term benefits Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided, or upon the actual absence of the employee when the benefit is not accumulated. A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. The employee benefits are classified as short-term benefits or as other long-term benefits depending on when the Company expects the benefits to be wholly settled. (3) Share-based payment transactions The fair value of share-based payment, measured on the grant date, granted to employees is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect the number of awards that are expected to vest.
Provisions	I. Provisions A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation.
Revenue Recognition	J. Revenue Recognition General The Group recognizes revenue in accordance with IAS 18, Revenue Recognition · the significant risks and rewards of ownership of the goods have been transferred to the customer; · it is probable that the economic benefits associated with the transaction will flow to the Group; · the costs incurred or to be incurred in respect of the transaction can be measured reliably; · the Group retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; and · the amount of revenue can be measured reliably. The revenue from sales in the ordinary course of business is measured according to the fair value of the consideration received or receivable, which is based on the selling price of each component, net of discounts. In general, the Group’s sales agreements include several components: · surgical robotic-guidance systems (“Systems”); · disposable components; · related re-usable accessories; and · warranty and maintenance services related to the Systems sold, which includes spare parts, software updates, preventive maintenance and on-call support as detailed in the agreement. These components are split into separate accounting units if and only if each component has separate value for the customer and there is reliable evidence of the fair value of the components not yet supplied. Components not split into a separate accounting unit due to non-compliance with the above conditions, are grouped together as a single accounting unit. The revenue from each such accounting unit is recognized upon fulfillment of the conditions for recognition of revenue from the components included therein, according to their type. The allocation of consideration from a revenue arrangement to its separate units of account is based on the relative fair values of each unit. If the fair value of the delivered item is not reliably measurable, then revenue is allocated based on the difference between the total arrangement consideration and the fair value of the undelivered item. Usually, fair value of the warranty and maintenance services component is determined based on the renewal quote offered in the sales agreement. The timing of revenue recognition from the various components is as follows: Sales of Systems · Sales to end customers - Upon the completion of installation of the System, training of at least one surgeon, which typically occurs prior to or concurrent with the System installation, and customer acceptance, if required. · Sales to distributors - Upon delivery to the distributor, according to contractual delivery terms, provided that the significant risks and rewards of ownership of the System are transferred to the distributor upon delivery, the distributor has no right of return, receipt of the consideration is probable and not dependent on the distributor’s ability to collect from the end customer, the commitment to carry out installation and training for the end customer lies with the distributor and that the distributor has been authorized to perform the installation and training for the end customers, or if the distributor has the ability to perform the installation and training for the end customer independently. If the above conditions are not met, the Group recognizes revenue at the time of fulfillment of the conditions for recognition of revenue from the end customer For System sales, where a commitment for future trade-in exists, the Company examines whether the transaction meets all revenue recognition criteria. If one or more of the revenue recognition criteria are not met, revenue is deferred and the System is presented in inventory until the earliest of trade-in commitment is fulfilled, or trade-in option expire. In rare circumstances, the Company may bill a customer for a product and retain physical possession of the product until it is transferred to the customer at a point in time in the future. If such delivery is delayed at the customer’s request and the customer assumes title and accepts billing, revenue is recognized when the buyer takes title, provided that: (i) it is probable that the delivery will be made; (ii) the item is on hand, identified and ready for delivery to the customer at the time the sale is recognized; (iii) the customer specifically acknowledges the deferred delivery instructions, and (iv) the usual payment terms apply. Disposable components sales · In sales to end customers - Upon delivery. · In sales to distributors - Upon delivery to the distributor, provided that the significant risks and rewards of ownership of the components are transferred to the distributor upon delivery, the distributor has no right of return and that the receipt of the consideration is probable and not dependent on the distributor’s ability to collect from the end customer. Warranty and maintenance services (“Services”)
Leases	K. Leases Leases are classified as operating leases, and the leased assets are not recognized on the Group’s statement of financial position. Payments made under operating leases, are recognized in profit or loss on a straight-line basis over the term of the lease.
Financing income and expenses	L. Financing income and expenses Financing income is comprised of interest income on funds invested, changes in the fair value of financial assets at fair value through profit or loss, changes in fair value of derivative instruments and foreign currency gains. Interest income is recognized as it accrues using the effective interest method. Financing expenses are comprised of changes in fair value of derivative instruments, as well as changes in the fair value of financial assets at fair value through profit or loss and foreign currency losses. In the statements of cash flows, interest received and interest paid are presented as part of cash flows from operating activities. Foreign currency gains and losses are reported on a net basis.
Taxes on income	M. Taxes on income Taxes on income are comprised of current and deferred tax. Current tax is the expected tax payable (or receivable) on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date. Deferred tax is recognized with respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. A deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which that can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. A provision for uncertain tax positions, including additional tax and interest expenses, is recognized when it is more probable than not that the Group will have to use its economic resources to pay the obligation. Tax benefit arising from tax deduction on exercise of share options is recognized in statement of profit or loss to the extent of the cumulative remuneration expense recognized. Any excess benefit is recognized directly in equity. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity.
Loss per share	N. Loss per share The Group presents basic and diluted loss per share data for its ordinary shares. Basic loss per share is calculated by dividing the loss attributable to ordinary shareholders of the Group by the weighted average number of ordinary shares outstanding during the year. Diluted loss per share is determined by adjusting the loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares, which are comprised of share options and share options granted to employees and warrants held by investors.
Comprehensive income	O. Comprehensive income The Group has no comprehensive income components other than net income or loss.

Significant Accounting Polici34

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of significant accounting policies [Abstract]
Schedule of Estimated Useful Lives	The estimated useful lives for the current and comparative periods are as follows: Computers and equipment 3 years Machinery and equipment 3-10 years Motor vehicles 7 years Office furniture and equipment 6-17 years Leasehold improvements The shorter of the lease term and the useful life

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2017
Cash and cash equivalents [abstract]
Schedule of Cash and Cash Equivalents	December 31 2017 2016 USD thousands USD thousands Current balances in banks 31,072 14,784 Deposits held at financial institutions, with original maturity periods of up to three months 15,304 170 46,376 14,954

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of associates [abstract]
Schedule of Breakdown according to Type of Investment	December 31 2017 2016 USD thousands USD thousands Short-term investments Deposits held at financial institutions, in USD (*)56,693 (*)37,849 Investments in marketable securities Mutual funds 15 13 56,708 37,862 Long-term investments Deposits held at financial institutions, in USD 5,171 9,017

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of other current assets [Abstract]
Schedule of Other Current Assets	December 31 2017 2016 USD thousands USD thousands Institutions 1,027 1,127 Prepaid expenses 421 254 Interest receivable 271 171 Advances to suppliers 32 1 Other receivables 303 175 2,054 1,728

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2017
Classes of current inventories [abstract]
Schedule of Inventory	December 31 2017 2016 USD thousands USD thousands Raw materials and spare parts 3,199 1,634 Work in progress 187 232 Finished goods 4,478 2,849 7,864 4,715

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of detailed information about property, plant and equipment [abstract]
Schedule of Property and Equipment, Net	Office Machinery furniture Computers Motor and and Leasehold and vehicles equipment equipment improvements equipment Total USD thousands Cost Balance as of January 1, 2017 - 3,613 214 820 1,495 6,142 Additions - 1,601 87 170 264 2,122 Disposals (*) - (313 ) - - (81 ) (394 ) Balance as of December 31, 2017 - 4,901 301 990 1,678 7,870 Balance as of January 1, 2016 33 1,880 193 301 1,236 3,643 Additions - 1,765 31 828 313 2,937 Disposals (33 ) (32 ) (10 ) (309 ) (54 ) (438 ) Balance as of December 31, 2016 - 3,613 214 820 1,495 6,142 Depreciation Balance as of January 1, 2017 - 1,345 67 3 1,112 2,527 Depreciation for the year - 771 19 185 214 1,189 Disposals (*) - (88 ) - - (81 ) (169 ) Balance as of December 31, 2017 - 2,028 86 188 1,245 3,547 Balance as of January 1, 2016 26 954 64 188 979 2,211 Depreciation for the year 3 423 13 124 185 748 Disposals (29 ) (32 ) (10 ) (309 ) (52 ) (432 ) Balance as of December 31, 2016 - 1,345 67 3 1,112 2,527 Carrying amount Balance as of January 1, 2016 7 926 129 113 257 1,432 Balance as of December 31, 2016 - 2,268 147 817 383 3,615 Balance as of December 31, 2017 - 2,873 215 802 433 4,323 (*) In 2017 the Company sold two Mazor X systems that were classified as fixed assets to one of its customers. The depreciated value of the two systems was USD 225 thousand.

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of detailed information about intangible assets [abstract]
Schedule of Intangible Assets	Presented hereunder is the movement in the carrying amount of intangible assets during the years 2017 and 2016: Capitalized development costs USD thousands Cost Balance as of December 31, 2017 and 2016 2,332 Amortization Balance as of December 31, 2016 74 Amortization for the year ended December 31, 2017 333 Balance as of December 31, 2017 407 Carrying amount December 31, 2016 2,258 December 31, 2017 1,925

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Other Current Liabilities Schedule Of Other Current Liabilities Details
Schedule of Deferred Income	December 31 2017 2016 USD thousands USD thousands Other deferred income 3,471 2,197 Deferred income relating to trade-in arrangements - 1,834 3,471 4,031
Schedule of Other Current Liabilities	December 31 2017 2016 USD thousands USD thousands Salary and related liabilities 5,114 4,905 Accrued expenses 4,280 3,029 Institutions 234 300 Tax provision 8 8 Related parties* 76 45 Other 162 175 9,874 8,462 * See Note 21 - Related Parties, for additional information regarding transactions and balances with related parties.

Employee Benefits (Tables)

Employee Benefits (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of defined benefit plans [abstract]
Schedule of Post-Employment Benefit Plans - Defined Contribution Plan	For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Amount recognized as expense in respect of defined contribution plan 462 368 243

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of taxes on income [Abstract]
Schedule of Composition of Income Tax Expense	For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Current tax expense Current tax 23 265 97 Prior year taxes (50 ) - - Deferred tax expense ( benefit Changes in deferred tax assets\ liabilities in subsidiary (129 ) (221 ) 116 Total tax expense (benefit) (156 ) 44 213
Sechedule of Reconciliation Between Theoretical Tax on Pre-Tax Profit and Tax Expense	For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Loss before taxes on income (12,575 ) (18,624 ) (15,172 ) Primary tax rate of the Company 24 % 25 % 26.5 % Tax calculated according to the Company’s primary tax rate (3,018 ) (4,656 ) (4,021 ) Changes to tax in respect of: Different tax rate of foreign subsidiaries 122 94 54 Non-deductible expenses 1, 658 1,179 875 Tax losses and benefits for which deferred tax assets were not created 1, 077 3,583 3,290 Tax losses and benefits for which deferred Prior years taxes (50 ) - - Other differences 55 (156 ) 15 Income tax expense (benefit) (156 ) 44 213
Schedule of Deferred Tax Assets and Liabilities	The Company has recognized deferred tax assets and liabilities in respect of the following items: December 31 2017 2016 USD thousands USD thousands Property and equipment (44 ) (102 ) Tax losses and other temporary differences 431 360 Deferred tax assets 387 258
Schedule of Unrecognized Deferred Tax Assets	Deferred tax assets have not been recognized in respect of the following items: December 31 2017 2016 USD thousands USD thousands Deductible temporary differences, net 6,091 5,034 Capital tax losses 7, 461 7,486 Operating tax losses 114,345 92,089

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2017
Buildings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Minimum Annual Lease Payments	The lease payments for buildings in Israel are linked to the CPI and for those in the U.S. are stated at the U.S. dollar. The minimum annual lease payments under the agreements are as follows: December 31, 2017 USD thousands 2018 713 2019 26 2020 626 2021 313 2,278
Motor Vehicles [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Minimum Annual Lease Payments	The minimum annual payments according to the agreements are as follows: December 31, 2017 USD thousands 2018 456 2019 333 2020 103 892

Revenues (Tables)

Revenues (Tables)	12 Months Ended
	Dec. 31, 2017
Revenue [abstract]
Schedule of Revenues	For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Sales of systems 37,071 19,624 13,373 Sales of disposables 16,246 10,295 7,648 Services and other 11,630 6,460 5,075 64,947 36,379 26,096

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of operating segments [abstract]
Schedule of Information on Geographical Areas	For the year ended December 31, 2017 U.S.A. International Total USD in thousands Total revenues 59,525 5,422 64,947 For the year ended December 31, 2016 U.S.A. International Total USD in thousands Total revenues 30,716 5,663 36,379 For the year ended December 31, 2015 U.S.A. International Total USD in thousands Total revenues 20,271 5,825 26,096 * Virtually all of the Company’s long-lived assets are located in Israel.

Cost of Sales (Tables)

Cost of Sales (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of cost of sales [Abstract]
Schedule of Cost of Sales	For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Materials and subcontractors 18,483 7,503 3,669 Salaries, wages and related expenses 2,732 1,474 1,264 Depreciation and amortization 871 418 193 Other manufacturing expenses 1,598 935 701 Total cost of sales 23,684 10,330 5,827

Research and Development Expe48

Research and Development Expenses, net (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of research and development expenses [Abstract]
Schedule of Research and Development Expenses	For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Materials and subcontractors 2,037 2,444 2,690 Salaries, wages and related expenses 5,488 4,167 2,875 Depreciation 131 97 45 Patent registration expenses 135 208 106 Overhead 942 539 355 Other research and development expenses 386 613 253 9,119 8,068 6,324 Less: capitalized cost - (2,332 ) - co-development participation (927 ) - - Total research and development expenses 8,192 5,736 6,324

Selling and Marketing Expenses

Selling and Marketing Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of selling and marketing expenses [Abstract]
Schedule of Selling and Marketing Expenses	For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Salaries, wages and related expenses 27,716 22,270 16,143 Consultation 2,926 2,439 1,834 Advertising, demonstrations and exhibitions 1,994 3,243 2,546 Travel expenses 4,627 3,814 2,696 Depreciation 451 259 213 Excise tax - - 308 Overhead 998 919 707 Other selling and marketing expenses 787 693 500 Total selling and marketing expenses 39,499 33,637 24,947

General and Administrative Ex50

General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of general and administrative expenses [Abstract]
Schedule of General and Administrative Expenses	For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Salaries, wages and related expenses 4,535 3,525 2,395 Professional services 1,802 1,510 1,271 Travel expenses 216 192 214 Overhead 445 203 133 Other general and administrative expenses 377 267 292 Total general and administrative expenses 7,375 5,697 4,305

Financing Income and Expenses (

Financing Income and Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of financing income and expenses [Abstract]
Schedule of Financing Income and Expenses	For the year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Interest income and net change in fair value of receivable interest 701 399 269 Net income from change in exchange rates 501 - - Hedging transactions 45 39 3 Financing income recognized in profit or loss 1,247 438 272 Net expenses from change in exchange rates - (10 ) (113 ) Other financing expenses (19 ) (31 ) (24 ) Financing expenses recognized in profit or loss (19 ) (41 ) (137 ) Net financing income 1,228 397 135

Related Parties (Tables)

Related Parties (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of transactions between related parties [abstract]
Schedule of Key Management Personnel Compensation (Including Directors)	Compensation to key management personnel (including one director) that are employed by the Group: For the year ended December 31 2017 2016 2015 Number USD Number of USD Number USD of people thousands people thousands of people thousands Employee benefits 11 3,270 9 2,752 9 2,092 Share-based payments 11 1,841 9 1,865 9 1,285 5,111 4,617 3,377 Compensation to directors: For the year ended December 31 2017 2016 2015 Number USD Number of USD Number USD of people thousands people thousands of people thousands Total compensation to directors employed by the Company* 1 387 1 199 1 187 Compensation to independent directors** 4 753 5 354 4 423 * Including share-based payments in the amount of USD 255 thousand, USD 82 thousand and USD 78 thousand in 2017, 2016 and 2015, respectively. ** Including share-based payments in the amount of USD 519 thousand, USD 194 thousand and USD 287 thousand in 2017, 2016 and 2015, respectively.

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of classes of share capital [abstract]
Schedule of Share capital	December 31 Number of Ordinary shares 2017 2016 Thousands of shares of NIS 0.01 par value Issued and paid-in share capital as of January 1 47,619 42,352 Issuance of share capital to investors , see note 22C(2) 2,080 3,917 Exercise of warrants by investors , see note 22C(1) - 134 Exercise of share options by employees , see note 23 2,383 1,216 Issued and paid-in share capital as of December 31 52,082 47,619 Authorized share capital 75,000 75,000
Schedule of Warrants Held by Investors	December 31 Number of options 2017 2016 Thousands of options and warrants of NIS 0.01 par value Number of outstanding options and warrants as of January 1 - 134 Issued during the period 2,420 (*) - Exercised during the period - (134 ) Number of outstanding options and warrants as of December 31 2,420 - (*) The amount of 2,420 thousand warrants represent the number of shares to be issued, pursuant to exercise of 1,210 thousand warrants issued to Medtronic, in connection with a private issuance in 2017. For further details see note 22(C)(2).

Share-Based Payments (Tables)

Share-Based Payments (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Schedule of Number and Weighted Average Exercise Prices of Share Options	Weighted Weighted average Weighted average exercise Number of average Number of exercise Number of price* options exercise price* options price* options 2017 2017 2016 2016 2015 2015 US dollars US dollars US dollars Balance at January 1 6.45 6,668,441 5.43 5,531,623 5.43 4,540,158 Forfeited during the year 7.99 (387,447 ) 6.83 (235,718 ) 7.09 (364,408 ) Exercised during the year 6.27 (2,382,927 ) 3.59 (1,216,115 ) 1.70 (218,277 ) Granted during the year 19.15 882,250 7.04 2,588,651 6.76 1,574,150 Outstanding at December 31 9.76 4,780,317 6.45 6,668,441 5.43 5,531,623 Exercisable at December 31 7.68 1,595,666 5.19 1,882,267 2.91 1,949,459 * The exercise price is denominated in NIS.
Schedule of Grant Terms and Parameters Used to Determine Fair Value of Benefit for Grants	The parameters used in the measurement of the fair value Share price Contractual that served Total Vesting life of the Average as a basis fair value of Grant date Number of Period options Interest Expected exercise for pricing the benefit on DD/MM/YEAR Offerees instruments (Years) (Years) rate Volatility** price* the option* the grant date % % USD USD USD thousands 29/01/2015 Officer and consultant 110,000 2-4 7 1.5 48.61 5.83 5.35 268 15/02/2015 Employees 104,250 2-4 7 1.65 48.65 5.86 5.86 269 26/02/2015 Officer 100,000 1.5-3.5 7 1.44 48.69 6.28 5.82 261 04/05/2015 Employees and consultant 144,500 2-4 7 1.36 48.88 6.44 6.44 440 15/07/2015 Officers, employees and consultants 941,900 2-4 7 2.03 48.84 7.17 7.17 3,269 08/10/2015 CEO 60,000 2-4 6.77 1.7 49.37 7.01 5.75 153 29/10/2015 Employees 113,500 2-4 7 1.64 48.92 5.81 5.56 294 14/02/2016 Employees and consultants 112,500 2-4 7 1.48 49.25 5.32 4.35 216 02/05/2016 Employee 42,500 2-4 7 1.52 48.14 6.06 6.06 120 10/05/2016 Consultant 25,000 2-4 7 1.47 48.10 5.91 5.58 68 18/05/2016 Officers and employees 1,424,327 2-4 1.95-7.00 0.24-1.5 44.22-48.72 5.80 5.35 3,474 19/07/2016 CEO 386,574 2-4 6.77 1.43 46.83 5.77 9.98 2,333 28/07/2016 Officer, Employees and consultant 116,900 2-4 7 0.18-1.42 46.06-46.73 9.79 9.79 531 06/11/2016 Employees 240,850 2-4 1.48-7.00 0.22-1.64 45.94-46.63 11.57 11.06 1,209 28/11/2016 Directors 240,000 1-3 6.88-7.00 1.90-1.94 46.60-46.62 11.71 11.40 1,266 14/02/2017 Employees 201,500 2-4 1.21-7.00 0.20-1.95 46.34-46.38 11.52 10.93 1,009 04/05/2017 Employees and Consultant 74,500 2-4 0.99-7.00 0.17-1.84 46.68-49.97 17.95 17.95 642 15/06/2017 Employees and Officers 245,750 2-4 0.87-7.00 0.11-1.68 46.76-48.25 19.56 17.62 1,936 23/08/2017 Employees and Consultants 125,500 2-4 7.00 1.26 47.22 19.39 19.18 1,120 07/09/2017 Consultant 50,000 2 7.00 1.33 47.35 23.60 23.60 582 03/10/2017 Officer 135,000 2-4 7.00 1.40 47.34 25.04 25.04 1,611 05/11/2017 Consultant 50,000 2-4 7.00 1.37 47.70 28.75 28.75 714 * The exercise price and share price are denominated in NIS and are re-measured using historic exchange rates. ** Expected volatility is estimated by considering historic share price volatility of the Company. The risk-free interest rate was determined on the basis of non-interest bearing NIS-denominated Government debentures with a remaining life equal to the expected term of the options.

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings per share [abstract]
Schedule of Loss Attributable to Ordinary Shareholders	For the year ended December 31 2017 2016 2015 USD Thousands USD Thousands USD Thousands Loss for the year 12,419 18,668 15,385
Schedule of Weighted Average Number of Ordinary Shares	For the year ended December 31 2017 2016 2015 USD Thousands USD Thousands USD Thousands Balance as of January 1 47,619 42,352 42,133 Effect of shares issued during the year 1,535 2,529 151 Weighted average number of ordinary shares used to calculate basic loss per share 49,154 44,881 42,284

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure of detailed information about financial instruments [abstract]
Schedule of Exposure to Credit Risk	The maximum exposure to credit risk for cash and cash equivalents, deposits, short-term investments, trade receivables and long-term investments at the reporting date by type of counterparty was: December 31 2017 2016 Carrying Carrying amount amount USD thousands Cash and cash equivalents 46,376 14,954 Mutual funds 15 13 Short-term investments - bank deposits 56,693 37,849 Trade receivables 6,056 8,225 Other current assets 271 171 Long-term investments - bank deposits 5,171 9,017 114,582 70,229
Schedule of Exposure to Credit Risk for Trade Receivables at Reporting Date	The maximum exposure to credit risk for trade receivables at the reporting date by geographic region was as follows: December 31 2017 2016 USD thousands Israel 819 29 United States 4,644 7,503 Asia Pacific 75 497 Rest of the world 518 196 6,056 8,225
Schedule of Aging of Debts and Impairment Losses	The aging of trade receivables at the reporting date was: December 31 2017 2016 USD thousands Not past due 5,610 7,986 Past due 0-30 days 417 215 Past due 31-60 days 19 24 Past due 61-90 days 5 - Past due over 90 days 5 - 6,056 8,225
Schedule of Exposure to Linkage and Foreign Currency Risk	The Group’s exposure to linkage and foreign currency risk was as follows based on notional amounts: December 31, 2017 New Israeli Shekels Unlinked CPI Linked CPI US dollar Euro Non - monetary Total USD thousands Current Assets Cash and cash equivalents 9,977 - 35,812 587 - 46,376 Short-term investments 15 - 56,693 - - 56,708 Trade receivables 223 - 4,719 518 - 5,460 Other current assets 974 - 422 - 658 2,054 Inventory - - - - 7,864 7,864 Total current assets 11,189 - 97,646 1,105 8,522 118,462 Other non-current assets - 132 - - 387 519 Trade receivables 596 - - - - 596 Property and equipment, net - - - - 4,323 4,323 Intangible assets, net - - - - 1,925 1,925 Long-term investments - - 5,171 - - 5,171 Total assets 11,785 132 102,817 1,105 15,157 130,996 Current Liabilities Trade payables 1,275 - 2,199 - - 3,474 Deferred revenue - - - - 3,471 3,471 Other current liabilities 3,560 - 6,028 24 262 9,874 Total current liabilities 4,835 - 8,227 24 3,733 16,819 Employee benefits - - - - 414 414 Total liabilities 4,835 - 8,227 24 4,147 17,233 Total balance, net 6,950 132 94,590 1,081 11,010 113,763 December 31, 2016 New Israeli Shekels Unlinked CPI Linked CPI US dollar Euro Non- Total Current Assets USD thousands Cash and cash equivalents 2,300 - 11,923 731 - 14,954 Short-term investments 287 - 37,575 - - 37,862 Trade receivables 29 - 8,000 196 - 8,225 Other current assets 977 - 231 - 520 1,728 Inventory - - - - 4,715 4,715 Total current assets 3,593 - 57,729 927 5,235 67,484 Other non-current assets - 93 - - 258 351 Property and equipment, net - - - - 3,615 3,615 Intangible assets, net - - - - 2,258 2,258 Long-term investments - - 9,017 - - 9,017 Total assets 3,593 93 66,746 927 11,366 82,725 Current Liabilities Trade payables 1,615 - 3,264 139 - 5,018 Deferred revenue - - - - 4,031 4,031 Other current liabilities 2,676 - 5,440 18 328 8,462 Total current liabilities 4,291 - 8,704 157 4,359 17,511 Employee benefits - - - - 325 325 Total liabilities 4,291 - 8,704 157 4,684 17,836 Total balance, net (698 ) 93 58,042 770 6,682 64,889
Schedule of Information Regarding CPI and Significant Exchange Rates	Information regarding the CPI and significant exchange rates: For the year ended December 31, For the year ended December 31, 2017 2016 2015 2017 2016 2015 % of change Spot price of 1 USD at the reporting date 1 NIS 10.9 1.5 (0.3 ) 0.2884 0.2601 0.2563 1 Euro 13.9 (3.4 ) (10.4 ) 1.1978 1.0517 1.0884 CPI in points * 0.4 (0.2 ) (1.0 ) 113.05 112.60 112.82 * According to an average basis of 2008
Schedule of Exposure to Linkage and Foreign Currency Risk in Respect of Derivatives	The Group’s exposure to linkage and foreign currency risk in respect of derivatives is as follows: Currency/ Currency/ linkage linkage Amount Amount Date of receivable payable receivable payable Expiration Fair value NIS thousands USD thousands USD thousands December 31, 2017 Instruments not accounted for as hedging: Buy put options NIS USD 1,500 435 Jan-March 2018 3.6 Sell call options NIS USD 1,500 414 Jan-March 2018 (0.4 ) 3.2 December 31, 2016 Instruments not accounted for as hedging: Forward NIS USD 4,000 (1,039 ) Jan-March 2017 2 2
Schedule of Reporting Date Interest Rate Profile	At the reporting date the interest rate profile of the Group’s interest-bearing financial instruments was as follows: December 31 2017 2016 Carrying Carrying amount amount USD thousands USD thousands Fixed rate instruments Deposits held at financial institutions, with original maturity periods of up to three months 15,304 170 Short-term investments 56,693 37,849 Long-term investments 5,171 9,017 77,168 47,036 Variable rate instruments Mutual funds 15 13 15 13

Reporting Entity (Details)

Reporting Entity (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Sep. 30, 2017	Aug. 31, 2016	May 31, 2016	Dec. 31, 2017	Sep. 11, 2017	Dec. 31, 2016	Dec. 31, 2015	May 28, 2013
Disclosure of detailed information about business combination [line items]
American Depositary Shares								2
Shares issued				47,619,000		42,352,000	42,133,000
ADSs [Member] | Medtronic [Member] | Warrants [Member]
Disclosure of detailed information about business combination [line items]
Shares issued					1,210,000
Exercise price					$ 44.83
Medtronic [Member]
Disclosure of detailed information about business combination [line items]
Fully diluted basis price		$ 21.84	$ 11.42
Purchase agreement amount			$ 11.9	$ 40
Proceeds from equity issuance		$ 20
Medtronic [Member] | Ordinary shares [Member]
Disclosure of detailed information about business combination [line items]
Ordinary shares issued	1,040,107	1,831,384	2,085,984
Medtronic [Member] | ADSs [Member]
Disclosure of detailed information about business combination [line items]
Ordinary shares issued	2,080,214	915,692	1,042,992
Fully diluted basis price	$ 38.46

Significant Accounting Polici58

Significant Accounting Policies (Narrative) (Details)	12 Months Ended
	Dec. 31, 2017
Capitalized development costs [Member]
Disclosure of detailed information about intangible assets [line items]
Estimated useful life of intangible assets	7 years

Significant Accounting Polici59

Significant Accounting Policies (Schedule of Estimated Useful Lives) (Details)	12 Months Ended
	Dec. 31, 2017
Computers and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	3 years
Machinery and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	3-10 years
Motor Vehicles [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	7 years
Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	6-17 years
Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	The shorter of the lease term and the useful life

Cash and Cash Equivalents (Narr

Cash and Cash Equivalents (Narrative) (Details) - Fixed interest rate [Member]	12 Months Ended
	Dec. 31, 2017
Bottom of range [Member]
Disclosure of financial assets [line items]
Annual interest rate on deposits	0.01%
Top of range [Member]
Disclosure of financial assets [line items]
Annual interest rate on deposits	1.47%

Cash and Cash Equivalents (Sche

Cash and Cash Equivalents (Schedule of Cash and Cash Equivalents) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash and cash equivalents [abstract]
Current balances in banks	$ 31,072	$ 14,784
Deposits held at financial institutions, with original maturity periods of up to three months	15,304	170
Cash and cash equivalents	$ 46,376	$ 14,954	$ 13,519	$ 22,255

Investments (Narrative) (Detail

Investments (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Disclosure of financial assets [line items]
Restricted cash	$ 1,107	$ 1,331
Fixed interest rate [Member] | Bottom of range [Member]
Disclosure of financial assets [line items]
Annual interest rate on investment deposits	0.86%
Fixed interest rate [Member] | Top of range [Member]
Disclosure of financial assets [line items]
Annual interest rate on investment deposits	2.00%

Investments (Schedule of Breakd

Investments (Schedule of Breakdown According to Type of Investment) (Details) - USD ($) $ in Thousands		Dec. 31, 2017	Dec. 31, 2016
Short-term investments
Deposits held at financial institutions, in USD	[1]	$ 56,693	$ 37,849
Investments in marketable securities
Mutual funds		15	13
Short-term investments		56,708	37,862
Long-term investments
Deposits held at financial institutions, in USD		$ 5,171	$ 9,017
[1]	Including restricted cash in the amount of USD 1,107 thousand for bank guarantees.

Other Current Assets (Schedule

Other Current Assets (Schedule of Other Current Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of other current assets [Abstract]
Institutions	$ 1,027	$ 1,127
Prepaid expenses	421	254
Interest receivable	271	171
Advances to suppliers	32	1
Other receivables	303	175
Other current assets	$ 2,054	$ 1,728

Inventory (Schedule of Inventor

Inventory (Schedule of Inventory) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Classes of current inventories [abstract]
Raw materials and spare parts	$ 3,199	$ 1,634
Work in progress	187	232
Finished goods	4,478	2,849
Inventory	$ 7,864	$ 4,715

Property and Equipment, net (Sc

Property and Equipment, net (Schedule of Property and Equipment, Net) (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about property, plant and equipment [line items]
Balance		$ 3,615
Balance		4,323	$ 3,615
Deprecated value of two systems		225
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		6,142	3,643
Additions		2,122	2,937
Disposals	[1]	(394)	(438)
Balance		7,870	6,142
Cost [Member] | Motor Vehicles [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance			33
Additions
Disposals	[1]		(33)
Balance
Cost [Member] | Machinery and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		3,613	1,880
Additions		1,601	1,765
Disposals	[1]	(313)	(32)
Balance		4,901	3,613
Cost [Member] | Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		214	193
Additions		87	31
Disposals	[1]		(10)
Balance		301	214
Cost [Member] | Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		820	301
Additions		170	828
Disposals	[1]		(309)
Balance		990	820
Cost [Member] | Computers and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		1,495	1,236
Additions		264	313
Disposals	[1]	(81)	(54)
Balance		1,678	1,495
Depreciation [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		2,527	2,211
Depreciation		1,189	748
Disposals	[1]	(169)	(432)
Balance		3,547	2,527
Depreciation [Member] | Motor Vehicles [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance			26
Depreciation			3
Disposals	[1]		(29)
Balance
Depreciation [Member] | Machinery and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		1,345	954
Depreciation		771	423
Disposals	[1]	(88)	(32)
Balance		2,028	1,345
Depreciation [Member] | Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		67	64
Depreciation		19	13
Disposals	[1]		(10)
Balance		86	67
Depreciation [Member] | Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		3	188
Depreciation		185	124
Disposals	[1]		(309)
Balance		188	3
Depreciation [Member] | Computers and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		1,112	979
Depreciation		214	185
Disposals	[1]	(81)	(52)
Balance		1,245	1,112
Carrying amount [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		3,615	1,432
Balance		4,323	3,615
Carrying amount [Member] | Motor Vehicles [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance			7
Balance
Carrying amount [Member] | Machinery and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		2,268	926
Balance		2,873	2,268
Carrying amount [Member] | Office furniture and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		147	129
Balance		215	147
Carrying amount [Member] | Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		112	113
Balance		802	112
Carrying amount [Member] | Computers and equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Balance		383	257
Balance		$ 257	$ 383
[1]	In 2017 the Company sold two Mazor X systems that were classified as fixed assets to one of its customers. The depreciated value of the two systems was USD 225 thousand.

Intangible Assets (Schedule of

Intangible Assets (Schedule of Intangible Assets) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Disclosure of detailed information about intangible assets [line items]
Balance	$ 2,258
Balance	1,925
Cost [Member]
Disclosure of detailed information about intangible assets [line items]
Balance	2,332
Balance	2,332
Amortization [Member]
Disclosure of detailed information about intangible assets [line items]
Balance	74
Amortization	333
Balance	407
Carrying amount [Member]
Disclosure of detailed information about intangible assets [line items]
Balance	2,258
Balance	$ 1,925

Other Current Liabilities (Sche

Other Current Liabilities (Schedule of Deferred Income) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Current Liabilities Schedule Of Other Current Liabilities Details
Other deferred income	$ 3,471	$ 2,197
Deferred income relating to trade-in arrangements		1,834
Deferred revenue	$ 3,471	$ 4,031

Other Current Liabilities (Sc69

Other Current Liabilities (Schedule of Other Current Liabilities) (Details) - USD ($) $ in Thousands		Dec. 31, 2017	Dec. 31, 2016
Other Current Liabilities Schedule Of Other Current Liabilities Details
Salary and related liabilities		$ 5,114	$ 4,905
Accrued expenses		4,280	3,029
Institutions		234	300
Tax provision		8	8
Related parties	[1]	76	45
Other		162	175
Other current liabilities		$ 9,874	$ 8,462
[1]	See Note 21 - Related Parties, for additional information regarding transactions and balances with related parties.

Employee Benefits (Schedule of

Employee Benefits (Schedule of Post-Employment Benefit Plans - Defined Contribution Plan) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of defined benefit plans [abstract]
Amount recognized as expense in respect of defined contribution plan	$ 462	$ 368	$ 243

Taxes on Income (Narrative) (De

Taxes on Income (Narrative) (Details) - USD ($) $ in Thousands	Jan. 04, 2016	Aug. 05, 2013	Jan. 31, 2017	Dec. 22, 2016	Jul. 31, 2009	Apr. 30, 2004	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate							24.00%	25.00%	26.50%
Change in corporate tax rate	Reduced by 1.5% to a rate of 25%		7.5% in Development Zone A and 12% elsewhere, or 6% in case of a ‘Special Preferred Technological Enterprise’	Reduced from 25% to 23% in two steps.
Period of losses of subsidiary in USA							20 years
Utilization of the subsidiary's tax losses					$ 207
Ownership change in percentage							50.00%
Period of ownership change							three-year
Ownership percentage							5.00%
Carry-forward operating tax losses							$ 96,307
Carry-forward capital tax losses							$ 7,486
Percentage of tax to dividend distribution to corporate shareholder who is not an Israeli resident							4.00%
Percentage of amount of foreign investors in distributing dividends							90.00%
Subsidiary in the U.S. [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate							34.00%
Carry-forward operating tax losses							$ 19,882
Patents and know-how serving [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Estimated useful life of intangible assets							8-year
Bottom of range [Member] | Subsidiary in the U.S. [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
State tax rate							0.75%
Top of range [Member] | Subsidiary in the U.S. [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
State tax rate							9.99%
First step [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Change in corporate tax rate				The first step will be to a rate of 24% as from January 2017
Second step [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Change in corporate tax rate				The second step will be to a rate of 23% as from January 2018.
Benefits under Israeli Law for Encouragement of Capital Investments [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate						25.00%	20.00%
Period of tax exempt						two years
Period of tax rate in following years						5 years
Period of beginning of year of selection						12 years
Period of benefits of tax		10 consecutive years
Benefits under Israeli Law for Encouragement of Capital Investments [Member] | Bottom of range [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate						10.00%
Benefits under Israeli Law for Encouragement of Capital Investments [Member] | Top of range [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate						25.00%
Special Preferred Technological Enterprise [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate							20.00%
Israel [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate							24.00%	25.00%	26.50%
Israel [Member] | Subsidiary in the U.S. [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate							12.50%
Development Area A [Member] | Benefits under Israeli Law for Encouragement of Capital Investments [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate		9.00%
Change in corporate tax rate		Reduced tax rate of 5%
Development Area A [Member] | Benefits under Israeli Law for Encouragement of Capital Investments [Member] | Bottom of range [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate							7.50%
Development Area A [Member] | Benefits under Israeli Law for Encouragement of Capital Investments [Member] | Top of range [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate							9.00%
Rest of country [Member] | Benefits under Israeli Law for Encouragement of Capital Investments [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate		16.00%
Change in corporate tax rate		8% in the rest of the country.
U.S.A. [Member] | Subsidiary in the U.S. [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Corporate tax rate							17.50%

Taxes on Income (Schedule of Co

Taxes on Income (Schedule of Composition of Income Tax Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current tax expense
Current tax	$ 23	$ 265	$ 97
Prior year taxes	(50)
Deferred tax expense (benefit)
Changes in deferred tax assets\liabilities in subsidiary	(129)	(221)	116
Income tax expense (benefit)	$ (156)	$ 44	$ 213

Taxes on Income (Sechedule of R

Taxes on Income (Sechedule of Reconciliation Between Theoretical Tax on Pre-Tax Profit and Tax Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of taxes on income [Abstract]
Loss before taxes on income	$ (12,575)	$ (18,624)	$ (15,172)
Primary tax rate of the Company	24.00%	25.00%	26.50%
Tax calculated according to the Company's primary tax rate	$ (3,018)	$ (4,656)	$ (4,021)
Changes to tax in respect of:
Different tax rate of foreign subsidiaries	122	94	54
Non-deductible expenses	1,658	1,179	875
Tax losses and benefits for which deferred tax assets were not created	$ 1,077	$ 3,583	$ 3,290
Tax losses and benefits for which deferred prior years taxes	(5000.00%)
Other differences	$ 55	$ (156)	$ 15
Income tax expense (benefit)	$ (156)	$ 44	$ 213

Taxes on Income (Schedule of De

Taxes on Income (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	$ 387	$ 258
Property and equipment [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	(44)	(102)
Tax losses and other temporary differences [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax assets	$ 431	$ 360

Taxes on Income (Schedule of Un

Taxes on Income (Schedule of Unrecognized Deferred Tax Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of taxes on income [Abstract]
Deductible temporary differences, net	$ 6,091	$ 5,034
Capital tax losses	7,461	7,486
Operating tax losses	$ 114,345	$ 92,089

Commitments (Narrative) (Detail

Commitments (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about property, plant and equipment [line items]
Commitment to pay	$ 15
Security for building lease	304
Prepaid expenses	421	$ 254
Outstanding purchase commitments for inventory components and R&D materials	3,819	5,590
Buildings [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Lease payments	853	648
Motor Vehicles [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Lease payments	$ 454	309
Operating lease period	32 to 36 months
Prepaid expenses	$ 132	$ 93

Commitments (Minimum Annual Lea

Commitments (Minimum Annual Lease Payments) (Details) $ in Thousands	Dec. 31, 2017USD ($)
Buildings [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual lease payments	$ 2,278
Buildings [Member] | 2018 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual lease payments	713
Buildings [Member] | 2019 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual lease payments	626
Buildings [Member] | 2020 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual lease payments	626
Buildings [Member] | 2021 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual lease payments	313
Motor Vehicles [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual lease payments	892
Motor Vehicles [Member] | 2018 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual lease payments	456
Motor Vehicles [Member] | 2019 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual lease payments	333
Motor Vehicles [Member] | 2020 [Member]
Disclosure of finance lease and operating lease by lessee [line items]
Minimum annual lease payments	$ 103

Revenues (Schedule of Revenues)

Revenues (Schedule of Revenues) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue [abstract]
Sales of systems	$ 37,071	$ 19,624	$ 13,373
Sales of disposables	16,246	10,295	7,648
Services and other	11,630	6,460	5,075
Revenues	$ 64,947	$ 36,379	$ 26,096

Segment Reporting (Narrative) (

Segment Reporting (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of geographical areas [line items]
Total revenues	$ 64,947	$ 36,379	$ 26,096
Customers One [Member]
Disclosure of geographical areas [line items]
Total revenues	$ 14,400

Segment Reporting (Schedule of

Segment Reporting (Schedule of Information on Geographical Areas) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of geographical areas [line items]
Total revenues	$ 64,947	$ 36,379	$ 26,096
U.S.A. [Member]
Disclosure of geographical areas [line items]
Total revenues	59,525	30,716	20,271
International [Member]
Disclosure of geographical areas [line items]
Total revenues	$ 5,422	$ 5,663	$ 5,825

Cost of Sales (Schedule of Cost

Cost of Sales (Schedule of Cost of Sales) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of cost of sales [Abstract]
Materials and subcontractors	$ 18,483	$ 7,503	$ 3,669
Salaries, wages and related expenses	2,732	1,474	1,264
Depreciation and amortization	871	418	193
Other manufacturing expenses	1,598	935	701
Total cost of sales	$ 23,684	$ 10,330	$ 5,827

Research and Development Expe82

Research and Development Expenses, net (Schedule of Research and Development Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of research and development expenses [Abstract]
Materials and subcontractors	$ 2,037	$ 2,444	$ 2,690
Salaries, wages and related expenses	5,488	4,167	2,875
Depreciation	131	97	45
Patent registration expenses	135	208	106
Overhead	942	539	355
Other research and development expenses	386	613	253
Research and development expenses	9,119	8,068	6,324
Less: capitalized cost		(2,332)
Co-development participation	(927)
Total research and development expenses, net	$ 8,192	$ 5,736	$ 6,324

Selling and Marketing Expense83

Selling and Marketing Expenses (Schedule of Selling and Marketing Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of selling and marketing expenses [Abstract]
Salaries, wages and related expenses	$ 27,716	$ 22,270	$ 16,143
Consultation	2,926	2,439	1,834
Advertising, demonstrations and exhibitions	1,994	3,243	2,546
Travel expenses	4,627	3,814	2,696
Depreciation	451	259	213
Excise tax			308
Overhead	998	919	707
Other selling and marketing expenses	787	693	500
Total selling and marketing expenses	$ 39,499	$ 33,637	$ 24,947

General and Administrative Ex84

General and Administrative Expenses (Schedule of General and Administrative Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of general and administrative expenses [Abstract]
Salaries, wages and related expenses	$ 4,535	$ 3,525	$ 2,395
Professional services	1,802	1,510	1,271
Travel expenses	216	192	214
Overhead	445	203	133
Other general and administrative expenses	377	267	292
Total general and administrative expenses	$ 7,375	$ 5,697	$ 4,305

Financing Income and Expenses85

Financing Income and Expenses (Schedule of Financing Income and Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of financing income and expenses [Abstract]
Interest income and net change in fair value of receivable interest	$ 701	$ 399	$ 269
Net income from change in exchange rates	501
Hedging transactions	45	39	3
Financing income recognized in profit or loss	1,247	438	272
Net expenses from change in exchange rates		(10)	(113)
Other financing expenses	(19)	(31)	(24)
Financing expenses recognized in profit or loss	(19)	(41)	(137)
Financing income, net	$ 1,228	$ 397	$ 135

Related Parties (Narrative) (De

Related Parties (Narrative) (Details) ₪ in Thousands, $ in Thousands	Jan. 02, 2018ILS (₪)	Jul. 19, 2016ILS (₪)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Disclosure of transactions between related parties [line items]
Share-based payments			$ 1,841	$ 1,865	$ 1,285
Bonus to CEO | ₪		₪ 900
NIS [Member]
Disclosure of transactions between related parties [line items]
CEO salary per month | ₪	₪ 90	₪ 80
Total compensation to directors employed by the Company [Member]
Disclosure of transactions between related parties [line items]
Share-based payments			255	82	78
Compensation to independent directors [Member]
Disclosure of transactions between related parties [line items]
Share-based payments			$ 519	$ 194	$ 287

Related Parties (Schedule of Ke

Related Parties (Schedule of Key Management Personnel Compensation (Including Directors)) (Details) $ in Thousands		12 Months Ended
		Dec. 31, 2017USD ($)People	Dec. 31, 2016USD ($)People	Dec. 31, 2015USD ($)People
Disclosure of transactions between related parties [abstract]
Employee benefits		$ 3,270	$ 2,752	$ 2,092
Share-based payments		1,841	1,865	1,285
Compensation to key management personnel		$ 5,111	$ 4,617	$ 3,377
Number of people | People		11	9	9
Total compensation to directors employed by the Company	[1]	$ 387	$ 199	$ 187
Total compensation to directors employed by the Company, Number of people | People	[1]	1	1	1
Compensation to independent directors	[2]	$ 753	$ 354	$ 423
Compensation to independent directors, Number of people | People	[2]	4	5	4
[1]	Including share-based payments in the amount of USD 255 thousand, USD 82 thousand and USD 78 thousand in 2017, 2016 and 2015, respectively.
[2]	Including share-based payments in the amount of USD 519 thousand, USD 194 thousand and USD 287 thousand in 2017, 2016 and 2015, respectively.

Equity (Narrative) (Details)

Equity (Narrative) (Details) ₪ / shares in Units, $ / shares in Units, ₪ in Thousands

Sep. 11, 2017USD ($)$ / sharesshares

Aug. 11, 2016USD ($)$ / sharesshares

May 25, 2016USD ($)$ / sharesshares

Feb. 21, 2016USD ($)shares

Feb. 21, 2016ILS (₪)shares

Dec. 31, 2017USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2011USD ($)shares$ / shares

Dec. 31, 2017₪ / sharesshares

Sep. 11, 2017₪ / sharesshares

Dec. 31, 2016₪ / sharesshares

Aug. 11, 2016₪ / sharesshares

May 25, 2016₪ / sharesshares

Dec. 31, 2015shares

Dec. 31, 2011₪ / shares

Disclosure of classes of share capital [line items]

Par value | ₪ / shares

₪ 0.01

₪ 0.01

Shares issued

47,619,000

42,352,000

42,133,000

Shares issued, Value | $

$ 39,978,000

$ 31,397,000

NIS [Member]

Disclosure of classes of share capital [line items]

Exercise price | ₪ / shares

₪ 80.15

₪ 42.02

ADSs [Member] | Medtronic [Member] | Warrants [Member]

Disclosure of classes of share capital [line items]

Exercise price | $ / shares

$ 44.83

Shares issued

1,210,000

1,210,000

Private placement - 2011 [Member]

Disclosure of classes of share capital [line items]

Grant date fair value of options | $

$ 1,020

Fair value of options | $

995,000

Proceeds from options | $

825,000

Share capital and premium | $

$ 5,561,000

Private placement - 2011 [Member] | Leader Issuances (1993) Ltd. [Member]

Disclosure of classes of share capital [line items]

Non-marketable options

168,421

Private placement - 2011 [Member] | Phoenix Group [Member]

Disclosure of classes of share capital [line items]

Non-marketable options

800,000

Private placement - 2011 [Member] | Ordinary shares [Member]

Disclosure of classes of share capital [line items]

Shares issued

134,421

134,421

Shares issued, Value | ₪

₪ 1,882

Private placement - 2011 [Member] | Ordinary shares [Member] | NIS [Member]

Disclosure of classes of share capital [line items]

Shares issued, Value | $

$ 481,000

Private placement - 2011 [Member] | Ordinary shares [Member] | Leader Issuances (1993) Ltd. [Member]

Disclosure of classes of share capital [line items]

Par value | ₪ / shares

₪ 0.01

Exercisable options

168,421

Options Term

five years

Exercise price | $ / shares

$ 3.88

Private placement - 2011 [Member] | Ordinary shares [Member] | Leader Issuances (1993) Ltd. [Member] | Warrants and Options [Member]

Disclosure of classes of share capital [line items]

Number of shares outstanding

421,053

Private placement - 2011 [Member] | Ordinary shares [Member] | Leader Issuances (1993) Ltd. [Member] | NIS [Member]

Disclosure of classes of share capital [line items]

Exercise price | ₪ / shares

14

Private placement - 2011 [Member] | Ordinary shares [Member] | Phoenix Group [Member]

Disclosure of classes of share capital [line items]

Par value | ₪ / shares

0.01

Exercisable options

800,000

Options Term

five years

Exercise price | $ / shares

$ 3.88

Private placement - 2011 [Member] | Ordinary shares [Member] | Phoenix Group [Member] | Warrants and Options [Member]

Disclosure of classes of share capital [line items]

Number of shares outstanding

2,000,000

Private placement - 2011 [Member] | Ordinary shares [Member] | Phoenix Group [Member] | NIS [Member]

Disclosure of classes of share capital [line items]

Exercise price | ₪ / shares

₪ 14

Private placement - 2016 [Member] | Medtronic [Member]

Disclosure of classes of share capital [line items]

Proceeds from issuance of shares | $

$ 40,000,000

$ 20,000,000

$ 11,911,000

Issuance expenses | $

$ 22,000

$ 249,000

$ 265,000

Private placement - 2016 [Member] | Ordinary shares [Member] | Medtronic [Member]

Disclosure of classes of share capital [line items]

Par value | ₪ / shares

₪ 0.01

₪ 0.01

₪ 0.01

Shares issued

2,080,212

1,831,384

2,085,984

2,080,212

1,831,384

2,085,984

Private placement - 2016 [Member] | Ordinary shares [Member] | Medtronic [Member] | Warrants [Member]

Disclosure of classes of share capital [line items]

Exercise price | $ / shares

$ 44.23

Shares issued

2,420,000

2,420,000

Private placement - 2016 [Member] | ADSs [Member] | Medtronic [Member]

Disclosure of classes of share capital [line items]

Par value | $ / shares

$ 21.84

$ 11.42

Price paid for the share/issuance price | $ / shares

$ 38.46

Shares issued

1,040,106

915,692

1,042,992

1,040,106

915,692

1,042,992

Private placement - 2016 [Member] | ADSs [Member] | Medtronic [Member] | Warrants [Member]

Disclosure of classes of share capital [line items]

Exercise price | $ / shares

$ 44.23

Shares issued

1,210,000

1,210,000

Equity (Schedule of Share capit

Equity (Schedule of Share capital) (Details) - ₪ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Disclosure of classes of share capital [abstract]
Issued and paid-in share capital as of January 1	47,619	42,352
Issuance of share capital to investors	2,080	3,917
Exercise of warrants by investors		134
Exercise of share options by employees	2,383	1,216
Issued and paid-in share capital as of December 31	52,082	47,619
Authorized share capital	75,000	75,000
Par value	₪ 0.01	₪ 0.01

Equity (Schedule of Warrants He

Equity (Schedule of Warrants Held by Investors) (Details) - ₪ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017		Dec. 31, 2016
Disclosure of classes of share capital [line items]
Number of outstanding options and warrants as of January 1			134
Issued during the period	2,420	[1]
Exercised during the period			(134)
Number of outstanding options and warrants as of December 31	2,420
Par value	₪ 0.01		₪ 0.01
Medtronic [Member]
Disclosure of classes of share capital [line items]
Issued during the period	1,210
[1]	The amount of 2,420 thousand warrants represent the number of shares to be issued, pursuant to exercise of 1,210 thousand warrants issued to Medtronic, in connection with a private issuance in 2017. For further details see note 22(C)(2).

Share-Based Expenses (Narrative

Share-Based Expenses (Narrative) (Details) $ in Thousands	1 Months Ended	12 Months Ended
	May 30, 2011shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2017shares₪ / shares	Dec. 31, 2016shares₪ / shares	Dec. 31, 2014shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options outstanding to purchase ordinary shares				5,531,623	4,780,317	6,668,441	4,540,158
Par value | ₪ / shares					₪ 0.01	₪ 0.01
Exercisable ordinary shares				1,949,459	1,595,666	1,882,267
Options granted		882,250	2,588,651	1,574,150
Total expense recognized as salary expense | $		$ 6,370	$ 4,439	$ 3,091
NIS [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price | ₪ / shares					₪ 80.15	₪ 42.02
Employees and directors [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options outstanding to purchase ordinary shares					4,780,317
Par value | ₪ / shares					₪ 0.01
Exercisable ordinary shares					1,595,666
2011 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	9,262,529
Period of options	10 years
Additional options available for grant					567,684

Share-Based Expenses (Schedule

Share-Based Expenses (Schedule of Number and Weighted Average Exercise Prices of Share Options) (Details)		12 Months Ended
		Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares
Weighted average exercise price
Balance at January 1 | $	[1]	$ 6.45	$ 5.43	$ 5.43
Forfeited during the year | $	[1]	7.99	6.83	7.09
Exercised during the year | $	[1]	6.27	3.59	1.7
Granted during the year | $	[1]	19.15	7.04	6.76
Outstanding at December 31 | $	[1]	9.76	6.45	5.43
Exercisable at December 31 | $	[1]	$ 7.68	$ 5.19	$ 2.91
Number of options
Balance at January 1 | shares		6,668,441	5,531,623	4,540,158
Forfeited during the year | shares		(387,447)	(235,718)	(364,408)
Exercised during the year | shares		(2,382,927)	(1,216,115)	(218,277)
Granted during the year | shares		882,250	2,588,651	1,574,150
Outstanding at December 31 | shares		4,780,317	6,668,441	5,531,623
Exercisable at December 31 | shares		1,595,666	1,882,267	1,949,459
[1]	The actual exercise price is denominated in NIS.

Share-Based Expenses (Schedul93

Share-Based Expenses (Schedule of Grant Terms and Parameters Used to Determine Fair Value of Benefit for Grants) (Details)	12 Months Ended
	Dec. 31, 2017USD ($)sharesYears
29/01/2015 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	29/01/2015
Offerees	Officer and consultant
Number of instruments | shares	110,000
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	7
Interest rate	1.50%
Expected volatility	48.61%	[1]
Average exercise price	$ 5.83	[2]
Share price that served as a basis for pricing the option	5.35	[2]
Total fair value of the benefit on the grant date	$ 268,000
15/02/2015 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	15/02/2015
Offerees	Employees
Number of instruments | shares	104,250
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	7
Interest rate	1.65%
Expected volatility	48.65%	[1]
Average exercise price	$ 5.86	[2]
Share price that served as a basis for pricing the option	5.86	[2]
Total fair value of the benefit on the grant date	$ 269,000
26/02/2015 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	26/02/2015
Offerees	Officer
Number of instruments | shares	100,000
Contractual life of the options (Years) | Years	7
Interest rate	1.44%
Expected volatility	48.69%	[1]
Average exercise price	$ 6.28	[2]
Share price that served as a basis for pricing the option	5.82	[2]
Total fair value of the benefit on the grant date	$ 261,000
26/02/2015 [Member] | Bottom of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Vesting Period (Years)	1.5
26/02/2015 [Member] | Top of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Vesting Period (Years)	3.5
04/05/2015 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	04/05/2015
Offerees	Employees and consultant
Number of instruments | shares	144,500
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	7
Interest rate	1.36%
Expected volatility	48.88%	[1]
Average exercise price	$ 6.44	[2]
Share price that served as a basis for pricing the option	6.44	[2]
Total fair value of the benefit on the grant date	$ 440,000
15/07/2015 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	15/07/2015
Offerees	Officers, employees and consultants
Number of instruments | shares	941,900
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	7
Interest rate	2.03%
Expected volatility	48.84%	[1]
Average exercise price	$ 7.17	[2]
Share price that served as a basis for pricing the option	7.17	[2]
Total fair value of the benefit on the grant date	$ 3,269,000
08/10/2015 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	08/10/2015
Offerees	CEO
Number of instruments | shares	60,000
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	6.77
Interest rate	1.70%
Expected volatility	49.37%	[1]
Average exercise price	$ 7.01	[2]
Share price that served as a basis for pricing the option	5.75	[2]
Total fair value of the benefit on the grant date	$ 153,000
29/10/2015 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	29/10/2015
Offerees	Employees
Number of instruments | shares	113,500
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	7
Interest rate	1.64%
Expected volatility	48.92%	[1]
Average exercise price	$ 5.81	[2]
Share price that served as a basis for pricing the option	5.56	[2]
Total fair value of the benefit on the grant date	$ 294,000
14/02/2016 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	14/02/2016
Offerees	Employees and consultants
Number of instruments | shares	112,500
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	7
Interest rate	1.48%
Expected volatility	49.25%	[1]
Average exercise price	$ 5.32	[2]
Share price that served as a basis for pricing the option	4.35	[2]
Total fair value of the benefit on the grant date	$ 216,000
02/05/2016 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	02/05/2016
Offerees	Employee
Number of instruments | shares	42,500
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	7
Interest rate	1.52%
Expected volatility	48.14%	[1]
Average exercise price	$ 6.06	[2]
Share price that served as a basis for pricing the option	6.06	[2]
Total fair value of the benefit on the grant date	$ 120,000
10/05/2016 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	10/05/2016
Offerees	Consultant
Number of instruments | shares	25,000
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	7
Interest rate	1.47%
Expected volatility	48.10%	[1]
Average exercise price	$ 5.91	[2]
Share price that served as a basis for pricing the option	5.58	[2]
Total fair value of the benefit on the grant date	$ 68,000
18/05/2016 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	18/05/2016
Offerees	Officers and employees
Number of instruments | shares	1,424,327
Vesting Period (Years)	2-4
Average exercise price	$ 5.8	[2]
Share price that served as a basis for pricing the option	5.35	[2]
Total fair value of the benefit on the grant date	$ 3,474,000
18/05/2016 [Member] | Bottom of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Contractual life of the options (Years) | Years	1.95
Interest rate	0.24%
Expected volatility	44.22%	[1]
18/05/2016 [Member] | Top of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Contractual life of the options (Years) | Years	7
Interest rate	1.50%
Expected volatility	48.72%	[1]
19/07/2016 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	19/07/2016
Offerees	CEO
Number of instruments | shares	386,574
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	6.77
Interest rate	1.43%
Expected volatility	46.83%	[1]
Average exercise price	$ 5.77	[2]
Share price that served as a basis for pricing the option	9.98	[2]
Total fair value of the benefit on the grant date	$ 2,333,000
28/07/2016 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	28/07/2016
Offerees	Officer, Employees and consultant
Number of instruments | shares	116,900
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	7
Average exercise price	$ 9.79	[2]
Share price that served as a basis for pricing the option	9.79	[2]
Total fair value of the benefit on the grant date	$ 531,000
28/07/2016 [Member] | Bottom of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Interest rate	0.18%
Expected volatility	46.06%	[1]
28/07/2016 [Member] | Top of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Interest rate	1.42%
Expected volatility	46.73%	[1]
06/11/2016 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	06/11/2016
Offerees	Employees
Number of instruments | shares	240,850
Vesting Period (Years)	2-4
Average exercise price	$ 11.57	[2]
Share price that served as a basis for pricing the option	11.06	[2]
Total fair value of the benefit on the grant date	$ 1,209,000
06/11/2016 [Member] | Bottom of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Contractual life of the options (Years) | Years	1.48
Interest rate	0.22%
Expected volatility	45.94%	[1]
06/11/2016 [Member] | Top of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Contractual life of the options (Years) | Years	7
Interest rate	1.64%
Expected volatility	46.63%	[1]
28/11/2016 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	28/11/2016
Offerees	Directors
Number of instruments | shares	240,000
Vesting Period (Years)	1-3
Average exercise price	$ 11.71	[2]
Share price that served as a basis for pricing the option	11.4	[2]
Total fair value of the benefit on the grant date	$ 1,266,000
28/11/2016 [Member] | Bottom of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Contractual life of the options (Years) | Years	6.88
Interest rate	1.90%
Expected volatility	46.60%	[1]
28/11/2016 [Member] | Top of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Contractual life of the options (Years) | Years	7
Interest rate	1.94%
Expected volatility	46.62%	[1]
14/02/2017 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	14/02/2017
Offerees	Employees
Number of instruments | shares	201,500
Vesting Period (Years)	2-4
Average exercise price	$ 11.52	[2]
Share price that served as a basis for pricing the option	10.93	[2]
Total fair value of the benefit on the grant date	$ 1,009,000
14/02/2017 [Member] | Bottom of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Contractual life of the options (Years) | Years	1.21
Interest rate	0.20%
Expected volatility	46.34%	[1]
14/02/2017 [Member] | Top of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Contractual life of the options (Years) | Years	7
Interest rate	1.95%
Expected volatility	46.38%	[1]
04/05/2017 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	04/05/2017
Offerees	Employees and Consultant
Number of instruments | shares	74,500
Vesting Period (Years)	2-4
Average exercise price	$ 17.95	[2]
Share price that served as a basis for pricing the option	17.95	[2]
Total fair value of the benefit on the grant date	$ 642,000
04/05/2017 [Member] | Bottom of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Contractual life of the options (Years) | Years	0.99
Interest rate	0.17%
Expected volatility	46.68%	[1]
04/05/2017 [Member] | Top of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Contractual life of the options (Years) | Years	7
Interest rate	1.84%
Expected volatility	49.97%	[1]
15/06/2017 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	15/06/2017
Offerees	Employees and Officers
Number of instruments | shares	245,750
Vesting Period (Years)	2-4
Average exercise price	$ 19.56	[2]
Share price that served as a basis for pricing the option	17.62	[2]
Total fair value of the benefit on the grant date	$ 1,936,000
15/06/2017 [Member] | Bottom of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Contractual life of the options (Years) | Years	0.87
Interest rate	0.11%
Expected volatility	46.76%	[1]
15/06/2017 [Member] | Top of range [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Contractual life of the options (Years) | Years	7
Interest rate	1.68%
Expected volatility	48.25%	[1]
23/08/2017 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	23/08/2017
Offerees	Employees and Consultants
Number of instruments | shares	125,500
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	7
Interest rate	1.26%
Expected volatility	47.22%	[1]
Average exercise price	$ 19.39	[2]
Share price that served as a basis for pricing the option	19.18	[2]
Total fair value of the benefit on the grant date	$ 1,120,000
07/09/2017 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	07/09/2017
Offerees	Consultant
Number of instruments | shares	50,000
Vesting Period (Years)	2
Contractual life of the options (Years) | Years	7
Interest rate	1.33%
Expected volatility	47.35%	[1]
Average exercise price	$ 23.6	[2]
Share price that served as a basis for pricing the option	23.6	[2]
Total fair value of the benefit on the grant date	$ 582,000
03/10/2017 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	3/10/2017
Offerees	Officer
Number of instruments | shares	135,000
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	7
Interest rate	1.40%
Expected volatility	47.34%	[1]
Average exercise price	$ 25.04	[2]
Share price that served as a basis for pricing the option	25.04	[2]
Total fair value of the benefit on the grant date	$ 1,611,000
05/11/2017 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Grant date DD/MM/YEAR	05/11/2017
Offerees	Consultant
Number of instruments | shares	50,000
Vesting Period (Years)	2-4
Contractual life of the options (Years) | Years	7
Interest rate	1.37%
Expected volatility	47.70%	[1]
Average exercise price	$ 28.75	[2]
Share price that served as a basis for pricing the option	28.75	[2]
Total fair value of the benefit on the grant date	$ 7,140,000
[1]	Expected volatility is estimated by considering historic share price volatility of the Company. The risk-free interest rate was determined on the basis of non-interest bearing NIS-denominated Government debentures with a remaining life equal to the expected term of the options.
[2]	The exercise price and share price are denominated in NIS and are re-measured using historic exchange rates.

Loss Per Share (Narrative) (Det

Loss Per Share (Narrative) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings per share [abstract]
Options excluded from diluted weighted average number of ordinary shares that were antidilutive	7,200	6,668	5,532

Loss Per Share (Schedule of Los

Loss Per Share (Schedule of Loss Attributable to Ordinary Shareholders) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings per share [abstract]
Loss for the year	$ 12,419	$ 18,668	$ 15,385

Loss Per Share (Schedule of Wei

Loss Per Share (Schedule of Weighted Average Number of Ordinary Shares) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Earnings per share [abstract]
Balance as of January 1	47,619	42,352	42,133
Effect of shares issued during the year	1,535	2,529	151
Weighted average number of ordinary shares used to calculate basic loss per share	49,154	44,881	42,284

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about financial instruments [abstract]
Period of payment of outstanding liabilities	6 months
Marketable securities	$ 15	$ 13
Derivative asset	$ 3	$ 2

Financial Instruments (Schedule

Financial Instruments (Schedule of Exposure to Credit Risk) (Details) - USD ($) $ in Thousands		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Disclosure of detailed information about financial instruments [abstract]
Cash and cash equivalents		$ 46,376	$ 14,954	$ 13,519	$ 22,255
Mutual funds		15	13
Short-term investments - bank deposits	[1]	56,693	37,849
Trade receivables		6,056	8,225
Other current assets		271	171
Long-term investments - bank deposits		5,171	9,017
Maximum exposure to credit risk, total		$ 114,582	$ 70,229
[1]	Including restricted cash in the amount of USD 1,107 thousand for bank guarantees.

Financial Instruments (Schedu99

Financial Instruments (Schedule of Exposure to Credit Risk for Trade Receivables at Reporting Date) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of financial assets [line items]
Trade receivables	$ 6,056	$ 8,225
Israel [Member]
Disclosure of financial assets [line items]
Trade receivables	819	29
United States [Member]
Disclosure of financial assets [line items]
Trade receivables	4,644	7,503
Asia Pacific [Member]
Disclosure of financial assets [line items]
Trade receivables	75	497
Rest of the world [Member]
Disclosure of financial assets [line items]
Trade receivables	$ 518	$ 196

Financial Instruments (Sched100

Financial Instruments (Schedule of Aging of Debts and Impairment Losses) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Disclosure of financial assets that are either past due or impaired [line items]
Trade receivables	$ 6,056	$ 8,225
Not past due [Member]
Disclosure of financial assets that are either past due or impaired [line items]
Trade receivables	5,610	7,986
Past due 0-30 days [Member]
Disclosure of financial assets that are either past due or impaired [line items]
Trade receivables	417	215
Past due 61-90 days [Member]
Disclosure of financial assets that are either past due or impaired [line items]
Trade receivables	5
Past due over 90 days [Member]
Disclosure of financial assets that are either past due or impaired [line items]
Trade receivables	5
Past due 31-60 days [Member]
Disclosure of financial assets that are either past due or impaired [line items]
Trade receivables	$ 19	$ 24

Financial Instruments (Sched101

Financial Instruments (Schedule of Exposure to Linkage and Foreign Currency Risk) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 46,376	$ 14,954	$ 13,519	$ 22,255
Short-term investments	56,708	37,862
Trade receivables	5,460	8,225
Other current assets	2,054	1,728
Inventory	7,864	4,715
Total current assets	118,462	67,484
Other non-current assets	519	351
Trade receivables	596
Property and equipment, net	4,323	3,615
Deferred tax asset	387	258
Intangible assets, net	1,925	2,258
Long-term investments	5,171	9,017
Total assets	130,996	82,725
Current Liabilities
Trade payables	3,474	5,018
Deferred revenue	3,471	4,031
Other current liabilities	9,874	8,462
Total current liabilities	16,819	17,511
Employee benefits	414	325
Total liabilities	17,233	17,836
Total balance, net	113,763	64,889
Unlinked CPI [Member]
Current Assets
Cash and cash equivalents	9,977	2,300
Short-term investments	15	287
Trade receivables	223	29
Other current assets	974	977
Inventory
Total current assets	11,189	3,593
Other non-current assets
Trade receivables	596
Property and equipment, net
Intangible assets, net
Long-term investments
Total assets	11,785	3,593
Current Liabilities
Trade payables	1,275	1,615
Deferred revenue
Other current liabilities	3,560	2,676
Total current liabilities	4,835	4,291
Employee benefits
Total liabilities	4,835	4,291
Total balance, net	6,950	(698)
Linked CPI [Member]
Current Assets
Cash and cash equivalents
Short-term investments
Trade receivables
Other current assets
Inventory
Total current assets
Other non-current assets	132	93
Trade receivables
Property and equipment, net
Intangible assets, net
Long-term investments
Total assets	132	93
Current Liabilities
Trade payables
Deferred revenue
Other current liabilities
Total current liabilities
Employee benefits
Total liabilities
Total balance, net	132	93
US dollar [Member]
Current Assets
Cash and cash equivalents	35,812	11,923
Short-term investments	56,693	37,575
Trade receivables	4,719	8,000
Other current assets	422	231
Inventory
Total current assets	97,646	57,729
Other non-current assets
Trade receivables
Property and equipment, net
Intangible assets, net
Long-term investments	5,171	9,017
Total assets	102,817	66,746
Current Liabilities
Trade payables	2,199	3,264
Deferred revenue
Other current liabilities	6,028	5,440
Total current liabilities	8,227	8,704
Employee benefits
Total liabilities	8,227	8,704
Total balance, net	94,590	58,042
Euro [Member]
Current Assets
Cash and cash equivalents	587	731
Short-term investments
Trade receivables	518	196
Other current assets
Inventory
Total current assets	1,105	927
Other non-current assets
Trade receivables
Property and equipment, net
Intangible assets, net
Long-term investments
Total assets	1,105	927
Current Liabilities
Trade payables		139
Deferred revenue
Other current liabilities	24	18
Total current liabilities	24	157
Employee benefits
Total liabilities	24	157
Total balance, net	1,081	770
Non - monetary [Member]
Current Assets
Cash and cash equivalents
Short-term investments
Trade receivables
Other current assets	658	520
Inventory	7,864	4,715
Total current assets	8,522	5,235
Other non-current assets	387	258
Trade receivables
Property and equipment, net	4,323	3,615
Intangible assets, net	1,925	2,258
Long-term investments
Total assets	15,157	11,366
Current Liabilities
Trade payables
Deferred revenue	3,471	4,031
Other current liabilities	262	328
Total current liabilities	3,733	4,359
Employee benefits	414	325
Total liabilities	4,147	4,684
Total balance, net	$ 11,010	$ 6,682

Financial Instruments (Sched102

Financial Instruments (Schedule of Information Regarding CPI and Significant Exchange Rates) (Details)		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
1 NIS [Member]
Disclosure of nature and extent of risks arising from financial instruments [line items]
% of change		10.90%	1.50%	(0.30%)
Closing CPI		0.2884	0.2601	0.2563
1 Euro [Member]
Disclosure of nature and extent of risks arising from financial instruments [line items]
% of change		13.90%	(3.40%)	(10.40%)
Closing CPI		1.1978	1.0517	1.0884
CPI in points [Member]
Disclosure of nature and extent of risks arising from financial instruments [line items]
% of change	[1]	0.40%	(0.20%)	(1.00%)
Closing CPI	[1]	113.05	112.60	112.82
[1]	According to an average basis of 2008 =100.

Financial Instruments (Sched103

Financial Instruments (Schedule of Exposure to Linkage and Foreign Currency Risk in Respect of Derivatives) (Details)	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2017ILS (₪)	Dec. 31, 2016ILS (₪)
Instruments not accounted for as hedging:
Fair value	$ 3,200	$ 2,000
Forward [Member]
Instruments not accounted for as hedging:
Currency/linkage receivable		NIS
Currency/linkage payable		USD
Amount receivable | ₪				₪ 4,000,000
Amount payable		$ (1,039,000)
Date of expiration		Jan-March 2016
Fair value		$ 2,000
Buy put options [Member]
Instruments not accounted for as hedging:
Currency/linkage receivable	NIS
Currency/linkage payable	USD
Amount receivable | ₪			₪ 1,500,000
Amount payable	$ 435,000
Date of expiration	Jan-March 2018
Fair value	$ 3,600
Sell call options [Member]
Instruments not accounted for as hedging:
Currency/linkage receivable	NIS
Currency/linkage payable	USD
Amount receivable | ₪			₪ 1,500,000
Amount payable	$ 414,000
Date of expiration	Jan-March 2018
Fair value	$ (400)

Financial Instruments (Sched104

Financial Instruments (Schedule of Reporting Date Interest Rate Profile) (Details) - USD ($) $ in Thousands		Dec. 31, 2017	Dec. 31, 2016
Fixed rate instruments
Deposits held at financial institutions, with original maturity periods of up to three months		$ 15,304	$ 170
Short-term investments	[1]	56,693	37,849
Long-term investments		5,171	9,017
Total Fixed rate instruments		77,168	47,036
Variable rate instruments
Mutual funds		15	13
Total Variable rate instruments		$ 15	$ 13
[1]	Including restricted cash in the amount of USD 1,107 thousand for bank guarantees.

Subsequent Events (Details)

Subsequent Events (Details) ₪ in Thousands, $ in Thousands	1 Months Ended		12 Months Ended
	Apr. 30, 2018USD ($)shares	Apr. 30, 2018ILS (₪)shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015shares
Disclosure of non-adjusting events after reporting period [line items]
Shares issued | shares			47,619,000	42,352,000	42,133,000
Shares issued, Value | $			$ 39,978	$ 31,397
Potential ordinary share transactions [Member] | 2003 Plan and 2011 Plan [Member]
Disclosure of non-adjusting events after reporting period [line items]
Shares issued | shares	573,608	573,608
Shares issued, Value | $	$ 4,126
Potential ordinary share transactions [Member] | 2003 Plan and 2011 Plan [Member] | NIS [Member]
Disclosure of non-adjusting events after reporting period [line items]
Shares issued, Value | ₪		₪ 14,453